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Abstract 
Leptin and adiponectin are the adipokines that are shown to exert pro-hypertrophic and 
anti-hypertrophic effects respectively, in cardiomyocytes. We sought to determine the 
direct interaction between the adipocytes and cardiomyocytes during endothelin-1 (ET-
1)-induced cardiomyocyte hypertrophy and determine the role of leptin and adiponectin. 
The adipose tissue conditioned medium (ACM) inhibited the ET-1-induced hypertrophy 
in a concentration-dependent manner and this anti-hypertrophic effect was more potent 
or reversed in the presence of leptin receptor antagonist (LRA; 0.1 nM) or adiponectin 
receptor-1 antibody (ARA; 100 ng/mL), respectively. ACM from heart failure rats 
induced by coronary artery ligation or obese rats did not mitigate the ET-1 induced 
hypertrophy in cardiomyocytes. 
These studies demonstrate that the net anti-hypertrophic activity of ACM in ET-1-
induced cardiac hypertrophy is likely mediated by adiponectin due activation of AMPK 
and determined by the leptin to adiponectin ratio. Heart failure and obese-induced 
pathology changes the characteristics of adipocytes although the underlying mechanisms 
for this effect are not completely known. 
 
Keywords 
Cardiac hypertrophy, heart failure, cardiomyocytes, leptin, adiponectin, ACM, 
adipocytes, ET-1, obesity. 
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1.1 Introduction 
Cardiovascular diseases (CVDs) are the number one cause of death worldwide (WHO 
2011). In Canada, someone dies of CVDs every 7 minutes (Statistics Canada (2011c, 
October)). Although statistics show that CVD related deaths have declined over time 
among Canadians (Tu et al. 2009), there is an increase in CVDs due to risk factors such 
as hypertension, diabetes and obesity in all age groups, especially among younger 
Canadians (Lee et al. 2009). 
1.2 Heart failure 
Heart failure affects more than 500,000 Canadians and more than 50,000 new patients 
are diagnosed each year (Ross et al. 2006). Heart failure cases are rarely found amongst 
individuals younger than 50 years, however, in those older than 50 years, the prevalence 
and incidence of heart failure increases progressively with age (Mosterd and Hoes 
2007). Heart failure is defined as the inability of the heart muscles to pump a sufficient 
amount of blood to meet the oxygen and blood demands of the body at normal filling 
pressure, which leads to dyspnoea, premature death and/or oedema. Heart failure is 
defined by the ejection fraction (EF) which is the ability of the heart to pump the blood 
out of the left and right ventricles on each beat. Based on EF, heart failure is categorised 
into two types: heart failure with preserved ejection fraction and heart failure with 
reduced ejection fraction. Heart failure with preserved EF is also known as diastolic 
heart failure whereas heart failure with reduced EF is also known as systolic heart 
failure. A number of epidemiology studies and clinical studies have examined the heart 
failure incidences in the population, it was observed that heart failure subjects were 
older people with a history of hypertension, obesity and type 2 diabetes mellitus (Lam et 
al. 2011, Brouwers et al. 2013). These risk factors were common in both types of heart 
failure (reduced and preserved EF) but incidence of heart failure and mortality were 
high for reduced EF (Brouwers et al. 2013).  
Risk factors of heart failure include hypertension, diabetes, smoking, obesity and 
coronary heart disease (NIH 2011). Heart failure symptoms include fatigue, numbness, 
3 
 
drowsiness, insomnia, anxiety, depression and chest pain resulting in reduced living 
quality (Blinderman et al. 2008). Based on Framingham Heart Study in adults, incidence 
of heart failure was dependent on body mass index. Overweight and obese people were 
at a higher risk of heart failure and this trend was evident between in both male and 
female (Kenchaiah et al. 2002). One population based study found that the heart failure 
risks increased in older people with diabetes compared with those without diabetes, 
suggesting a relationship between diabetes and heart failure (Bertoni et al. 2004). With 
an increasing number of heart failure patients and a resulting increase in healthcare 
costs, heart failure will be an increasing burden on society (Blinderman et al. 2008). 
Except for heart transplants, no cure exists for heart failure and prognosis is poor, as one 
third of the patients die within a year of diagnosis (Bleumink et al. 2004, McMurray and 
Pfeffer 2005).  
1.3 Heart failure & cardiac hypertrophy 
Association of cardiac hypertrophy with almost all forms of heart failure (Levy et al. 
1990) has aroused the great interest in understanding the molecular mechanism which 
leads to cardiac hypertrophy. The heart is composed of various types of cells such as 
myocytes and non-myocyte cells including fibroblasts, endothelial cells and vascular 
smooth muscle cells (Weber et al. 1992). When the normal heart is exposed to risk 
factors (chronic increases in pressure or volume overload), it first develops into 
compensatory phase cardiac hypertrophy in which cardiomyocytes grow in length 
and/or width in order to compensate for increased blood supply demand by improving 
cardiac pump function and reducing ventricular wall tension (compensated hypertrophy) 
(Haider et al. 1998, Berenji et al. 2005). However, if the wall tension is not relieved over 
time then this prolonged hypertrophy phase can progress towards heart failure as well as 
sudden death (Levy et al. 1990, Frey and Olson 2003). The presence of left ventricular 
hypertrophy is an important predictor for the development of heart failure (Maron 
1997). Therefore, studies are focused on finding new therapeutic approaches to prevent 
cardiac hypertrophy and heart failure. 
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1.4 Cardiac hypertrophy  
It has been two decades since studies linked cardiac hypertrophy and heart failure. 
Cardiac hypertrophy is an independent risk factor for myocardial infarction, angina 
pectoris, arrhythmia and cardiac sudden death (Levy et al. 1990). Several studies have 
proven that cardiac hypertrophy is positively associated with several risk factors such as 
diabetes (de Simone et al. 2002),  high blood pressure and obesity (Falkner et al. 2013). 
Cardiac hypertrophy is a general term for the heart’s condition when it experiences 
increased hemodynamic workload or when exposed to neurohumoral factors. 
Consequently, the heart enters a cardiac remodelling phase called cardiac hypertrophy in 
which cardiomyocytes grow in size leading to thickening of the ventricular walls (Frey 
et al. 2004). Based on the various types of stimuli, the heart develops into physiological 
or pathological hypertrophy and based on the response of the cardiomyocytes it shows 
two phenotypes: (1) concentric hypertrophy that is caused by pressure overload, in 
which sarcomeres are added in parallel and cell width increases, and (2) eccentric 
hypertrophy that is caused by volume overload, in which sarcomeres are added in series 
and cell length increases (Dorn et al. 2003) (Figure 1). 
1.4.1 Physiological hypertrophy 
Physiological hypertrophy is a type of cardiac hypertrophy which involves healthy 
growth of the heart in response to pregnancy-induced or exercise-induced events. This 
hypertrophied heart shows a different phenotype. For example, isotonic exercises such 
as running, cycling and swimming, causes volume overload resulting in eccentric 
hypertrophy and whereas isometric exercise such as weight lifting, causes pressure 
overload resulting in concentric hypertrophy (Pluim et al. 2000). This hypertrophy does 
not develop into heart failure (Fagard 1997, Pluim et al. 2000) and benefits the heart by 
up-regulating cardiac outflow at normal pressure. Generally, the morphology consists of 
incremental increases in myocyte volume and the formation of new sarcomeres. The end 
result of this hypertrophy is that the heart has normal or improved cardiac function. This 
type of hypertrophy is reversible and it does not show fibrosis or fetal gene up-
regulation which is seen in pathological hypertrophy (Beisvag et al. 2009).  
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Fig. 1. Physiological and pathological types of cardiac hypertrophy. Depending on 
the type of stimulus the normal heart responds differently. When the pressure overload 
stimuli are present, the heart develops into concentric hypertrophy and in the presence of 
volume overload stimuli; the heart develops into eccentric hypertrophy. “Adapted by 
permission from Macmillan Publishers Ltd: Nature Reviews Molecular Cell Biology 
(Maillet et al. 2013), copyright 2013.”  
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1.4.2 Pathological hypertrophy 
The pathological hypertrophy is the unhealthy growth of the heart in the response to 
stimuli with different pathological stimuli resulting in different types of hypertrophy. 
Hypertension or aortic constriction leads to pressure overload hypertrophy (Grossman et 
al. 1975) which develops into concentric phenotypic hypertrophy (Figure 1). On the 
other hand aortic valve disease leads to volume overload hypertrophy (Grossman et al. 
1975, Pluim et al. 2000) which develops into eccentric type of hypertrophy. This 
hypertrophy is initially compensatory where cardiomyocytes expand and the formation 
of new sarcomeres takes place which reduces wall stress. However, the hypertrophied 
heart does not remain in the compensatory phase and eventually transitions into a de-
compensatory phase leading to heart failure (Levy et al. 1990). Increased cardiac 
fibrosis, cardiomyocytes loss, cardiac dysfunction and risk of heart failure are associated 
with pathological hypertrophy (Weber et al. 1993, Cohn et al. 1997). The distinguished 
features of cardiac hypertrophy at the cellular level include increases in the 
cardiomyocytes size and enhanced rate of protein synthesis (Sugden and Clerk 1998). At 
the molecular level, hypertrophy is characterized by re-expression of the fetal genes, 
such as β-myosin heavy chain (β-MHC), α-skeletal actin and atrial natriuretic peptide 
(ANP) (Hefti et al. 1997). 
Generally, left ventricular hypertrophy occurs due to the resistance of outgoing blood 
flow from left ventricle to the whole body. On the other hand right ventricular 
hypertrophy is due to pulmonary hypertension (pressure in the pulmonary arteries). 
Pulmonary hypertension is caused by various factors including pulmonary blood vessel 
constriction and blood clot formation in the arteries. We will be referring to pathological 
cardiac hypertrophy throughout this manuscript. 
There are several mechanisms associated with cardiac hypertrophy. One pathway that 
plays an important role in cardiac hypertrophy is Ca2+/calmodulin-dependent kinase II 
(CaMKII). Intracellular Ca2+ is a cardiac contractility regulator and it is important to 
maintain appropriate levels in the heart, otherwise this could lead to pathological 
abnormalities such as arrhythmogenesis and prolonged tachycardia, eventually 
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culminating in heart failure (O'Rourke et al. 1999, Pogwizd et al. 1999). CaMKII are 
signal transducers of Ca2+ which regulate cellular actions mediated by Ca2+  (Braun and 
Schulman 1995). During cardiac hypertrophy, failing myocardium and heart failure 
expression and activity of CaMKII are increased (Netticadan et al. 2000, Hagemann et 
al. 2001, Anderson 2009). CaMKII overexpressing transgenic mice show dilated 
cardiomyopathy and cardiac hypertrophy accompanied by fibrosis (Zhang et al. 2003) 
which suggest a critical role of CaMKII during cardiac dysfunction. Another signalling 
mechanism is the calcium and calmodulin-activated protein phosphatase calcineurin.  
Elevation in intracellular calcium levels in cells activates calcineurin which then binds 
with the nuclear factor of activated T cells (NFAT), dephosphorylates NFAT, which 
causes NFAT activation and consequent translocation into the nucleus (Crabtree and 
Olson 2002). Studies in transgenic mice show that cardiac hypertrophy and heart failure 
are a result of either calcineurin or NFAT activation (Molkentin et al. 1998). 
Calcineurin/NFAT signalling is increased during cardiac hypertrophy and failing human 
heart. This signalling is absent during exercise induced hypertrophy which suggests that 
it is only associated with pathological hypertrophy and not with physiological 
hypertrophy (Wilkins et al. 2004). 
1.5 Cardiac hypertrophy in response to endothelin-1 (ET-1) 
ET-1 is a 21 amino acid peptide and a potent vasoconstrictor which has been shown to 
decrease heart rate and raise mean arterial blood pressure (Weitzberg et al. 1993). Its 
release is controlled in order to maintain homeostasis by means of blood pressure 
regulation (Somlyo and Somlyo 1993). This regulation is through Ca2+ channels (Miwa 
et al. 2005). ET-1 is produced from proendothelin-1 (38 amino acid precursor) by 
endothelin-converting enzyme (ECE). Obesity increases ET-1 protein and gene 
expression. During cardiac hypertrophy, both ET-1 and ET-1 binding sites are up-
regulated (Arai et al. 1995). High circulating levels of ET-1 in plasma have been 
reported to be positively correlated with obesity, hypertension and type 2 diabetes 
mellitus (Saito et al. 1990, Takahashi et al. 1990, Ferri et al. 1995). 
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ET-1 is also a neurohumoral factor which is released by cardiomyocytes (Nunez et al. 
1990, Suzuki et al. 1993, Yamazaki et al. 1996) during mechanical stretch-induced 
cardiac hypertrophy. ET-1 is also produced by vascular endothelial cells (Yanagisawa et 
al. 1988), cardiac fibroblast (Fujisaki et al. 1995) and macrophages (Fukuchi and Giaid 
1998) suggesting the autocrine and paracrine role of ET-1 on regulating cardiac 
functions. Two ET-1 receptors have been identified, ETA and ETB. Studies show that the 
ETA receptor exerts a vasoconstriction property (Zamora et al. 1993) while ETB receptor 
shows both vasoconstriction and vasodilation properties (Sato et al. 1995). In the rat 
myocardium, the ETA receptor is expressed widely (Hilal-Dandan et al. 1994). 
Cardiomyocyte secreted ET-1 in response to Angiotensin II (Ang II) treatment and 
blockage of ETA receptor attenuated the protein expression which was induced by Ang 
II thus suggesting that ET-1 contributes in the hypertrophic signals of Ang II through the 
ETA receptor in cardiomyocytes (Ito et al. 1993). Another study also found that in 
neonatal cardiomyocytes, ET-1 via ETA receptor induces the hypertrophic effect which 
includes activation of mitogen activated protein kinases (MAPK) and increased rate of 
protein synthesis (Yamazaki et al. 1996). 
1.6 Cardiac hypertrophy and obesity 
The rate of obesity and subsequent metabolic disorders are increasing worldwide. 
According to The World Health Organisation, globally in 2008, obesity incidences have 
increased almost 2 fold since 1980, and in 2008 the numbers of obese women were 1.5 
fold higher than men and total obese population was 11% (WHO 2008). Obesity is 
caused by accumulation of the adipose tissue (adiposity) in the different regions of the 
body which increases the likelihood of health problems and leads to reduced life 
expectancy (Haslam and James 2005). Obesity is defined by the body mass index (BMI) 
which is the person's body weight divided by the square of their height. According to 
distribution of the fat mass in the body, people are divided into 3 categories according to 
three BMI ranges; normal BMI ranges from 18.5 to 25 kg/m2, overweight BMI ranges 
from 25 to 30 kg/m2 and an obese BMI is equal to or more than 30 kg/m2 (WHO 1990). 
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Obesity is a chronic metabolic disorder linked with numerous comorbidities such as type 
2 diabetes mellitus, cancer, sleep apnea and ischemic stroke (Poirier and Eckel 2002, 
Suk et al. 2003, Forte et al. 2012). The alarming increase in the incidence of obesity has 
had a significant impact on the incidence of several cardiovascular abnormalities 
including hypertension (Lauer et al. 1992), cardiac hypertrophy (Turkbey et al. 2010) 
and heart failure (Kenchaiah et al. 2002). 
Studies are being carried out to better understand the factors and mechanisms involved 
in the heart’s remodelling during obesity. Cardiac remodelling includes left ventricular 
(LV) hypertrophy, left atrial (LA) enlargement, and impairment of LV systolic and 
diastolic function (Bugger and Abel 2008). These changes are believed to be the 
indicators of more serious complications such as cardiac dysfunction and heart failure 
(Abel et al. 2008).  
Many studies show link obesity with anatomical and physiological changes in the heart 
in both human and animal models (Abel et al. 2008). Association of obesity with the 
heart include LV hypertrophy evident in both human (Berkalp et al. 1995, Morricone et 
al. 2002, Avelar et al. 2007) and animal models (Barouch et al. 2003, Mazumder et al. 
2004, Barouch et al. 2006). Recent human studies on obese patients showed that LV 
hypertrophy was due to excessive accumulation of epicardial adipose tissue (Erdogan et 
al. 2013, Lin et al. 2013). Human studies also show the right ventricular and left atrium 
wall thickness and size were associated with obesity (Alpert et al. 1985, Alpert et al. 
1997, Wong et al. 2006). Animals study found triglyceride accumulation and cardiac 
fibrosis in the heart during obesity (Zhou et al. 2000, Toblli et al. 2005, Boudina and 
Abel 2006, Boudina et al. 2007). Impaired systolic function (Otto et al. 2004, Yue et al. 
2007) and diastolic function (Morricone et al. 2002, Christoffersen et al. 2003) was also 
observed during obesity in both human and animal studies.  
Although obesity is generally considered as increasing cardiovascular risk, a number of 
studies have reported that obese patients who are suffering from cardiovascular 
implications have better survival rate than normal weight people (Horwich et al. 2001, 
Lissin et al. 2002, Lavie and Milani 2003, Lavie et al. 2003, Hall et al. 2005). One study 
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showed that obese patients diagnosed with heart failure have improved life span in 
contrast with normal weight patients (Curtis et al. 2005). This obesity paradox is further 
supported by another study which suggested that patients hospitalized for heart failure 
and examined for 3 years showed significant lower mortality rate when they adjusted 
age, gender and severe illness (Hall et al. 2005). Similarly, obese subjects had either no 
effect or demonstrated improved life expectancy over both short term or and long term 
observation (Oreopoulos et al. 2008). Thus, some studies suggest that obesity may play 
a beneficial role in the patients who are diagnosed with cardiovascular disease. 
1.7 Adipokines  
Adipose tissue is widely distributed and major depots are found in both the visceral and 
subcutaneous regions. Adipose tissue is comprised of several types of cells including 
adipocytes, pre-adipocytes, endothelial cells and macrophages out of which adipocytes 
contributes about 50 to 70 percent (Hauner 2005).  Adipocytes contain triglycerides 
which are a source of energy reservoir to be used when needed (Ferguson and Leese 
2006). 
Since the discovery of leptin in 1994, adipose tissue is now recognized not only as an 
insulator of the body but also as an endocrine organ which secretes many bioactive 
compounds known as adipokines. White adipose tissue (WAT) is the principal source of 
adipokines which play important roles in regulating many bodily functions such as lipid 
metabolism, glucose metabolism as well as neuroendocrine and cardiovascular functions 
(Trujillo and Scherer 2006). Adipokines also regulate adipose tissue metabolism and 
affect other organs like muscle, pancreas, liver and brain (Kershaw and Flier 2004). 
There are more than 100 known adipokines including cytokines, chemokines and growth 
factors. Adipose tissue secreted some well-known adipokines including leptin, 
adiponectin, apelin and visfatin. Adipocytes have also been shown to release steroid 
hormones and prostaglandins (Hauner 2004, Staiger and Haring 2005). 
Adipocytes increase in size in obesity and their secretory properties changes which 
results in the release of more pro-inflammatory adipokines including leptin, TNF-alpha, 
some interleukins (IL-1, IL-6 and IL-8) and less anti-inflammatory adipokines such as 
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adiponectin (Jernas et al. 2006, Skurk et al. 2007) thus suggesting that size of adipocytes 
determines the release of adipokines. The number of macrophages in adipose tissue 
increases in obesity, and shows a positive relation with the size of adipocytes. Moreover, 
secretion of TNF-alpha has been discovered to be greater in macrophages than in 
adipocytes (Weisberg et al. 2003). Studies show that weight loss in obese patients 
increased anti-inflammatory factors and decreased both pro-inflammatory factors and 
macrophage infiltration (Clement et al. 2004, Cancello et al. 2005). 
A number of studies have reported that adipokines play an important role in regulating 
cardiac functions as evident in obese animal and obese knockout animal studies (Dong 
et al. 2006, Ren and Ma 2008, Amin et al. 2010, Guo et al. 2013). It has also been 
shown that adipokines are a potential link between obesity and heart failure (Schulze et 
al. 2003, Ouchi et al. 2006, Frankel et al. 2009, Ebert and Fasshauer 2011). Heart 
depends on the energy to maintain contractile functions and energy required by the heart 
is dependent on the metabolism of fatty acids. Metabolism of fatty acids is essential in 
order to prevent storage of triglyceride in the heart (McGavock et al. 2006). During 
obesity and diabetes increased fatty acid uptake, oxidation and decrease in glucose 
metabolism has been reported (Stanley et al. 2005, Abel et al. 2008). In the liver and 
skeletal muscles, it has been shown that adipokines maintain glucose and fatty acid 
metabolism (Badman and Flier 2007) and leptin (Palanivel et al. 2006) and adiponectin 
can regulate glucose uptake and fatty acid metabolism in cardiomyocytes  (Guo et al. 
2007, Palanivel et al. 2007). This suggests that adipokines maintain fatty acid and 
glucose metabolism and regulate homeostasis. A recent study analyzed the interaction 
between adipocytes obtained from human and animal and cardiomyocytes. It reported 
that adipocytes increased lipid accumulation and promoted apoptosis in HL-1 
cardiomyocytes with increased lipid droplets (Anan et al. 2011) which suggests that 
adipocytes induces lipotoxicity and apoptosis in the cardiomyocytes leading to heart 
failure. A study in 2006 reported that human adipocytes exert cardio-depressant activity 
in a dose-dependent manner and the molecular weights of the effective adipokines were 
between 10kDa and 30kDa, which suggests that adipokines in overweight patients may 
contribute to heart failure (Lamounier-Zepter et al. 2006). Another study revealed that 
adipose tissue derived from normal rats increased glucose uptake and fatty acid 
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oxidation in rat neonatal ventricular cardiomyocytes (Palanivel et al. 2008). However, 
adipose tissue derived from streptozotocin-induced diabetic rats had the ability to 
decrease oxidation of fatty acids and lower glucose uptake ability. These diabetic rats 
showed decreased levels of adiponectin and leptin expression and increased interleukin-
6 expression (Palanivel et al. 2008). Taken together these studies suggest that adipokines 
play a critical role to maintain homeostasis of the heart and cardiomyocytes. However, 
during pathological condition such as obesity and diabetes, alteration in the levels of 
adipokines (leptin and adiponectin) negatively affect the heart. Leptin and adiponectin 
have been studied extensively in terms of their cardiac effect, specifically cardiac 
hypertrophy.  
1.7.1 Leptin 
Leptin is a 16 kDa peptide product of the obesity (ob) gene (Zhang et al. 1994) 
discovered in 1994. It is secreted mainly by adipose tissue (Scherer et al. 1995) but 
organs including stomach (Bado et al. 1998), heart and cardiomyocytes (Purdham et al. 
2004, Rajapurohitam et al. 2006) also have the ability to produce leptin. Leptin secretion 
from heart and cardiomyocytes suggests that leptin could affect cardiac functions in 
autocrine and paracrine manner. Leptin circulates in the blood at concentrations between 
5-15 ng/mL in lean individuals (Sinha et al. 1996). The major physiological function of 
leptin is to decrease food intake and increase the energy consumption via signalling in 
the central nervous system. Leptin in the circulatory system affects central nervous 
system (CNS) in order to regulate energy balance in the body (Elmquist et al. 1998, 
Friedman and Halaas 1998). It is well known that energy expenditure and food intake is 
regulated by hypothalamus. Animal studies show that the hypothalamus expresses leptin 
binding sites (Stephens et al. 1995) and studies using in situ hybridisation show that 
many hypothalamus nuclei in mouse brain expresses OB-Rb gene expression abundantly 
(Mercer et al. 1996) suggesting that in hypothalamus OB-Rb could be the main receptor 
for leptin signaling. Another study shows that injection of leptin in mice directly 
activates STAT3 in hypothalamus in a dose-dependent manner (Vaisse et al. 1996). 
These data suggest that leptin acts on hypothalamus and contributes in the regulation of 
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the energy expenditure and food intake. Therefore it is known as circulating satiety 
factor (Jacob et al. 1997). 
Studies in both mice and humans suggest that the obese phenotype is associated with 
leptin gene mutation (Zhang et al. 1994, Montague et al. 1997, Strobel et al. 1998). 
Human subjects who had mutation in the leptin gene, observed low leptin levels 
regardless of their obesity (Montague et al. 1997, Strobel et al. 1998). These studies 
suggest that decreased production of leptin is due to improper leptin gene regulation 
which causes obesity. Leptin gene is essential for maintaining homeostasis through 
energy balance. However, plasma leptin levels are proportionate to adiposity; as adipose 
tissue abnormally accumulates in the body, the plasma leptin concentration also 
increases (Maffei et al. 1995, Considine et al. 1996). Obese subjects show high 
circulating leptin levels (Frederich et al. 1995). Though the levels of leptin in the plasma 
are high and leptin is known as a satiety hormone, leptin is unable to exert its effect 
during obesity. The possible cause for leptin’s inability to decrease weight in these 
patients might be due to hypothalamic leptin resistance (Seufert 2004). Some studies 
suggest the mechanism for leptin resistance. A study by Burguera et al found that obese 
rats had saturation of leptin receptors in the blood brain barriers (BBB) and leptin 
transport was decreased which could explain the leptin resistance in obese subjects 
(Burguera et al. 2000). Another study in diet-induced obesity in mice showed two 
reasons for the leptin resistance in hypothalamus, one was a defect in the leptin binding 
site in the hypothalamus which inhibited leptin-induced STAT3 signalling in the 
hypothalamus and the second was a defect in the intracellular signalling of leptin to 
activate STAT3 in the hypothalamus (El-Haschimi et al. 2000).  
Elevated plasma leptin levels have been observed in patients with left ventricular 
hypertrophy (Kartal et al. 2008), hypertension (Shankar and Xiao 2010),  myocardial 
infarction (Soderberg et al. 1999) ischemic heart disease (Wallace et al. 2001) as well as 
heart failure (Chan et al. 2003). Animal studies with regards to metabolic effects of 
leptin show that leptin addition to perfused heart elevates fatty acid oxidation, down-
regulates triglyceride contents and up-regulates oxygen consumption in the myocardium 
which decreases efficiency of the heart (Atkinson et al. 2002). Another study showed 
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that elevation in fatty acid oxidation was dependent on STAT3, nitric oxide and p38 
MAPK-dependent mechanism (Sharma et al. 2009) which are linked to the hypertrophic 
program. Long term treatment with leptin down-regulated fatty acid uptake which led to 
increased lipid accumulation in the HL-1 cardiomyocytes contradicts the result seen 
with short term leptin treatment (Palanivel et al. 2006). Direct effects of leptin in 
inducing hypertrophy in neonatal cardiomyocytes have been documented 
(Rajapurohitam et al. 2003, Zeidan et al. 2008). Leptin treatment increased reactive 
oxygen species (ROS) and ET-1 levels in neonatal cardiomyocytes which was inhibited 
by ET-1 receptor (ETA) antagonists; leptin induced cardiomyocyte hypertrophy was 
shown to be mediated through ET-1-ROS mechanism (Xu et al. 2004). 
1.7.1.1 Leptin signaling 
Leptin produces effects by binding with its receptors termed as OBRs (or LEPR) and are 
expressed in many tissues including pancreas, foetus, placenta, spleen, kidney, ovaries, 
heart and adipose tissue (Zhang et al. 1994, Kieffer et al. 1996, Hoggard et al. 1997, 
Chen et al. 1999). Leptin receptors exist in 6 isoforms (OB-Ra to OB-Rf) (Figure 2), and 
only the OB-Rb isoform has full signalling capacity regarding transduction of signals 
intracellularly in order to maintain homeostasis. This is supported by the study that show 
that mice which lacked the long form of the receptor showed similar phenotype 
compared with mice and animals which were leptin-deficient (ob/ob) (Chua et al. 1997, 
Friedman and Halaas 1998).  Being the long structure, OB-Rb has suitable binding site 
for Janus activated kinase 2/signal transducers and activators of transcription 3 
(JAK2/STAT3) signaling (Tartaglia 1997, White et al. 1997). During leptin signaling, 
leptin binds with the leptin receptor which changes the structural conformation of leptin 
receptor (OB-Rb homodimer) and phosphorylates JAK2 and JAK2 becomes activated 
(Devos et al. 1997, Tartaglia 1997, Couturier and Jockers 2003). Studies suggest that 
there are three intracellular known activation sites on the OB-Rb domain which upon 
phosphorylation become activated and conduct downstream leptin signaling that are: 
Tyr985, Tyr1077 and Tyr1138 (Tartaglia 1997, White et al. 1997, Banks et al. 2000, 
Hekerman et al. 2005, Gong et al. 2007). Only Tyr1138 creates binding site for STAT3 
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when phosphorylated which results in STAT3 to translocate to the nucleus and mediate 
the regulation of transcription (White et al. 1997, Banks et al. 2000). 
Leptin receptors are present in all types of cells including cardiomyocytes 
(Rajapurohitam et al. 2006). Several mechanisms have been proposed for leptin-induced 
cardiomyocytes hypertrophy in which leptin binds with the OB-Rb receptor and this 
leads to several downstream signaling cascades resulting in hypertrophy. During leptin-
induced hypertrophy mitogen activated protein kinase (MAPK) members such as 
extracellular signal-regulated kinase 1/2 (ERK1/2) and p38 are activated by leptin but 
not c-Jun N-terminal kinase whereas only p38 is involved in cardiac hypertrophy 
inhibition (Rajapurohitam et al. 2003). Leptin activated RhoA/ROCK pathway during 
hypertrophic effect and by blocking the RhoA/ROCK signalling, leptin-induced 
hypertrophic effect was attenuated in neonatal cardiomyocytes (Zeidan et al. 2006, 
Zeidan et al. 2008). RhoA/ROCK also translocated p38 MAPK into nucleus which 
mediated leptin induced cardiomyocyte hypertrophy (Zeidan et al. 2008). Leptin has 
been shown to mediate the hypertrophic effects of ET-1 and Ang II in the neonatal rat 
ventricular cardiomyocytes (Rajapurohitam et al. 2006). It has also been shown that 
leptin production is associated with other pro-hypertrophic factors such as endothelin-1 
and Ang II and these factors increase leptin production by activating NF-kB and p38 
MAPK pathway which translocated both NF-kB and p38 MAPK into nucleus and 
phosphorylated the p38 MAPK (Rajapurohitam et al. 2012). Taken together these 
findings suggest that leptin has detrimental effects on the heart. 
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Fig. 2: Structure of the leptin receptor (OB-R) isoforms (Karmazyn et al. 2007). 
“Reprinted from Trends in Cardiovascular Medicine, Volume 17, Karmazyn M., 
Purdham D. M., Rajapurohitam V., Zeidan A., Leptin as a cardiac hypertrophic factor: a 
potential target for therapeutics, Pages No. 206-11, Copyright 2007, with permission 
from Elsevier.”  
All the leptin receptor isoforms contain extracellular region, transmembrane and 
intracellular region except OB-Re which does not have intracellular region. The 
extracellular region has two cytokine receptor (CK) domains separated by one 
fibrinoactin type III (F3) domain and followed by three more fibrinoactin type III 
domains. In the intracellular region, all isoforms (Ob-Ra-Ob-Rd and Ob-Rf) contain box 
1 (B1). Only OB-Rb contains box 2 (B2) and box 3 (B3). In OB-Rb, box 1 and box 2 
bind with JAK and box 3 binds with STAT. All the receptor isoforms vary in their 
amino acid length range from 805 to 1162.  
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1.7.2  Adiponectin 
Adiponectin is a 30kDa protein also known as Acrp30 (adipocyte complement-related 
protein of 30 kDa). In addition to adipocytes, (Scherer et al. 1995) it is also synthesized 
by other organs such as placenta (Chen et al. 2006) and cardiomyocytes (Pineiro et al. 
2005). It was first isolated as cDNA in 1995 (Scherer et al. 1995) and has been of 
substantial research interest since as it is a protein that possesses anti-inflammatory 
(Ouchi et al. 2003), anti-tumor (Brakenhielm et al. 2004), anti-angiogenesis 
(Brakenhielm et al. 2004) and insulin sensitizing functions (Hotta et al. 2000). It is the 
most abundant circulating adipokine in healthy individuals ranging from 2-30 μg/mL 
(Shimada et al. 2004). Adiponectin circulates in two forms, full-length adiponectin 
(fAd) and globular adiponectin (gAd). Full-length adiponectin has a molecular weight 
30 kDa and exists in three forms trimer (low-molecular weight), hexamer (trimer-dimer) 
and multimer (high-molecular weight) (Nakano et al. 1996, Tsao et al. 2003, Waki et al. 
2003) where globular adiponectin exists only as a trimer. Adiponectin does not exist in 
the monomeric form in plasma (Pajvani et al. 2003). Adiponectin levels are decreased 
during obesity  (Arita et al. 1999), coronary artery disease (Nakamura et al. 2004) and in 
heart failure patients (Takano et al. 2009). In the liver, adiponectin improves insulin 
sensitivity (Nawrocki et al. 2006) and in skeletal muscle, fatty acid oxidation (Fruebis et 
al. 2001) by activating AMP-activated protein kinase (AMPK) which suggests that 
adiponectin plays an important role in regulating homeostasis.  
Adiponectin’s cardio-protective effect has been studied extensively. Knockout studies 
on mice observed that adiponectin deficient mice had enhanced myocardial apoptosis 
and increased infarct size compared to wild type animals and upon administration of 
adiponectin’s globular form significantly reduces apoptosis and infarct size (Shibata et 
al. 2005, Tao et al. 2007). Globular adiponectin administration also attenuated the 
peroxynitrile formation which protected the heart from the ischemic reperfusion injury 
in the adiponectin deficit mice (Tao et al. 2007) and ischemic perfusion injury was also 
protected through the mechanism of AMPK and COX-2 (Shibata et al. 2005). Another 
knockout study found that adiponectin deficient mice showed cardiac remodelling 
phenotype following transverse aortic constriction (TAC) compared to wild type mice. 
18 
 
They also showed low protein expression of AMPK which suggests that adiponectin is 
important to protect the hearts from pressure overloaded cardiac remodeling via 
activation of AMPK (Liao et al. 2005). It has been shown that long term activation of 
AMPK through pharmacological activator AICAR (5-Aminoimidazole-4-carboxamide-
1-β-d-ribofuranoside) attenuates cardiac hypertrophy induced by pressure overload (Li 
et al. 2007).  AICAR, in cytosol, is phosphorylated by adenosine kinase and converted 
into ZMP (AICA-riboside monophosphate), which is an AMP analogue that acts as 
AMP and activates AMPK (Corton et al. 1995). AICAR also attenuates cardiac 
hypertrophy through activating AMPK in both in vivo and in vitro (Meng et al. 2011) 
suggesting the role of AMPK as an anti-hypertrophic agonist. 
1.7.2.1 Adiponectin signaling 
The discovery of adiponectin receptors (AdipoR1 and AdipoR2) (Yamauchi et al. 2003) 
has unfolded various molecular pathways mediating the effect of adiponectin. Both 
receptors are widely expressed in the body including adipose tissue (Bluher et al. 2005, 
Rasmussen et al. 2006), pancreas (Staiger et al. 2005, Gu et al. 2006), osteoblasts 
(Berner et al. 2004, Kanazawa et al. 2007), brain (Kubota et al. 2007), muscle (Beylot et 
al. 2006, Dai et al. 2006), liver (Bonnard et al. 2008, Felder et al. 2010), heart (Ding et 
al. 2007, Palanivel et al. 2007) and leukocytes (Alberti et al. 2007, Weigert et al. 2008).  
AdipoR1 is abundantly expressed in skeletal muscles and AdipoR2 in liver (Yamauchi 
et al. 2003). The structure of adiponectin receptors are related to G protein-coupled 
receptors (GPCRs) but their sequence homology is very low. Adiponectin receptors 
contain intracellular N terminal and extracellular C terminal as opposed to G protein-
coupled receptors (Yamauchi et al. 2003) (figure 3).  
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Fig. 3: Adiponectin receptors (AdipoR1 & AdipoR2) structure (Yamauchi and 
Kadowaki 2013). “Reprinted from Cell Metabolism, Volume 17, Yamauchi, T., 
Kadowaki, T., Adiponectin Receptor as a Key Player in Healthy Longevity and Obesity-
Related Diseases, Pages no.  185–196, Copyright 2013, with permission from Elsevier.”  
The structure of AdipoR2 has 66.7% sequence homology with AdipoR1 and these 
receptors are different from G-protein coupled receptors. Unlike GPCRs these receptor 
have intracellular N terminal and extracellular C terminal.  
AdipoR1 possesses high-affinity towards the globular form of adiponectin and low-
affinity towards full-length form of adiponectin (Yamauchi et al. 2003). AdipoR1 in 
skeletal muscle has been shown to up-regulate glucose uptake and fatty acid oxidation 
by activation of AMPK (Yamauchi et al. 2003). AdipoR2 exerts intermediate affinity 
towards both globular form and full-length adiponectin and it mediates the effect of full-
length adiponectin by activating AMPK in the liver (Yamauchi et al. 2003). It is 
reported that in the neonatal cardiomyocyte AdipoR1 receptor is expressed more than 
AdipoR2 receptor (Palanivel et al. 2007). 
AdipoR1 mediates the protective effect of adiponectin against ischemic-reperfusion 
injury in mouse cardiomyocytes (Wang et al. 2010). Studies using mice show that 
adiponectin binds with APPL1 adaptor protein to induce and regulate downstream 
signaling (Mao et al. 2006, Wang et al. 2009). Pre-treatment with adiponectin protected 
rat embryonic cardiac myoblasts (H9c2) by reducing reactive oxygen species (ROS) 
production, which is up-regulated during hypoxia/reoxygenation injury, through 
AdipoR1 and APPL1 mediated signalling which suggests the anti-oxidative effect of 
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adiponectin (Park et al. 2011). APPL1 is expressed in a variety of tissues including 
skeletal muscle, brain, spleen and the heart (Mao et al. 2006). APPL1 is identified as an 
essential protein which interacts with AdipoR1 and AdipoR2 in adult rat 
cardiomyocytes (Fang et al. 2010). The coimmunoprecipitation study in the rat 
cardiomyocytes shows that adiponectin increases binding  of AdipoR1 to APPL1 but not 
AdipoR2 which leads to translocation of liver kinase B1 (LKB1) from the nucleus to 
cytosol and it is then bound with the AdipoR1-APPL1 complex which activates 
downstream AMPK phosphorylation which in turn regulates fatty acid metabolism 
(Fang et al. 2010). Studies in animals show that adiponectin attenuates Ang II (Shibata 
et al. 2004) and leptin-induced cardiac hypertrophy (Rajapurohitam et al. 2013) which 
suggests that adiponectin acts as an anti-hypertrophic agent.  
1.8 Hypothesis and objectives 
Rational: Adipose tissue is present throughout the body and adipose tissue-derived 
adipokines exerts various effects on different organs. The effect of individual adipokines 
on the cardiovascular system are under study. It is important to consider the effects 
induced by individual and combined adipokines on different organs and how those 
effects can alter the physiological response of the tissues. During obesity and cardiac 
hypertrophy, blood plasma levels of leptin are up-regulated and adiponectin levels 
decreased in comparison with healthy individual. Moreover, leptin possesses pro-
hypertrophic properties and adiponectin possesses anti-hypertrophic properties. Thus, 
we believe that the leptin and adiponectin play a critical role in mediating the cardiac 
hypertrophic response.  
Hypothesis: Adipocyte-derived leptin and adiponectin modulate ET-1-induced 
neonatal rat ventricular hypertrophy. 
Objective 1: To examine the potential effect of ACM on ET-1-induced cardiomyocyte 
hypertrophy. 
 To determine the effect of ACM we examine the role of leptin and adiponectin 
during hypertrophic response of ET-1 in cardiomyocytes.  
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Objective 2: To study the underlying signalling mechanism associated with the 
modulation of ET-induced cardiomyocyte hypertrophy by leptin/adiponectin.  
 In order to explore the signalling mechanism we focus on AMPK signalling as 
AMPK is associated with cardio-protective effect of adiponectin.  
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2. Materials and methods 
2.1 Primary culture of neonatal rat ventricular 
cardiomyocytes 
Neonatal hearts were extracted from 1-5 days old Sprague–Dawley rats (Charles River 
Canada, Montreal, Quebec, Canada). After sacrifice, hearts were isolated and rinsed in 
buffer containing 1x Hank’s balanced salt solution (HBSS) (Wisent Inc., St. Bruno, 
QC). Hearts were squeezed gently to remove residual blood and transferred to another 
dish containing fresh ice-cold 1x HBSS. Atrias were removed and ventricles were 
placed into another dish. Ventricles were minced into smaller pieces using a surgical 
blade. The heart pieces were then transferred into a water-jacketed Erlenmyer flask 
maintained at 37 oC after which digestion buffer was added for six sequential digestions. 
The digestion buffer contained 10% 10 x HBSS (Gibco, Life Technologies Burlington, 
ON, Canada), 2% 1 M HEPES (Gibco), 2% Penicillin/Streptomycin (Gibco), 0.11 
mg/mL Collagenase (Worthington Corp., Lakewood, NJ, USA), 0.13 mg/mL Trypsin 
(Worthington) and 0.03mg/mL DNase II (Worthington). In some early experiments, 
hearts were digested with 0.33mg/mL concentration without trypsin and DNase II 
(Figure 1-11). After each digestion, the supernatant was removed from the flask and 
poured into an Eppendorf tube having same volume of stop buffer which consisted of 
10% 10 x HBSS, 2% Penicillin/streptomycin and 20% Fetal Bovine Serum (FBS) to 
abolish collagenase activity. The solution containing both the supernatant and stop 
buffer was filtered in another Eppendorf tube using a 70 µm cell strainer and centrifuged 
at 2000 rpm at 4oC. The supernatant was discarded and pellets were re-suspended in the 
cell culture medium (Table 1). The suspension was subjected to pre-plating for one hour 
followed by another 30 min of pre-plating to ensure cardiomyocytes enrichment. 
Following pre-plating, Primaria™ (Falcon) culture dishes were plated with 
cardiomyocytes at an optimal density required for this type of experiment. Cells (1 x 104 
cells) were plated to perform cell surface area analysis as this quantity ensures sufficient 
density to visualise growth while 6 x 104 cells were plated for RNA and protein isolation 
as this quantity ensures sufficient density for gene expression and protein expression. 
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The cells were grown in an incubator at 37oC 5% CO2. After 48 hours, myocytes were 
washed with phosphate buffer saline-ABC (PBS-ABC) (Table 2) and cultured in serum-
free medium (Table 3) for another 24 hours before starting the treatments. Tissue culture 
medium pH were prepared at 7.10 and all the reagents were filtered, sterilized and 
autoclaved. 
2.2 Animal models for isolation of adipose tissue 
All the rats used in the experiments were 3-6 months old. 
After the rats were sacrificed, adipose tissue in normal Sprague-Dawley rats was 
isolated from the epididymal and perirenal region and in heart failure models and obese 
models adipose tissue was isolated from epididymal region.  
Heart failure model: To prepare heart failure model rats, coronary artery ligation 
(CAL) surgery was performed in adult Sprague-Dawley rats. Surgical procedure 
commenced after the rats were anesthetized by pentobarbital sodium (50 mg/kg body 
weight) which was administered by intraperitoneal injection. Rats were kept on a 
respirator (Model 683, Harvard Apparatus). The thoracotomy was performed and a 5-0 
braided silk suture was tied on the left main coronary artery at a distance of ~3 mm from 
the origin. To prepare heart failure control models (Sham), the ligature was positioned in 
a similar fashion and the silk suture was removed without tying. Four weeks after 
surgery, the rats were sacrificed and adipose tissue was isolated. 
Obese model: To obtain adipose tissue from obese model rats, JCR strain rats were 
used as they provide a suitable model of metabolic syndrome which is similar to humans 
(Russell and Koeslag 1990). The metabolic syndromes they show are abdominal 
obesity, mild type II diabetes and high risk for cardiovascular diseases (Russell and 
Koeslag 1990). The JCR rats are a unique strain that carries the mutant autosomal 
recessive cp gene, therefore, these strains are leptin receptor deficient (Koletsky 1975). 
Rats that are homozygous for the gene (cp/cp) develop obesity, insulin resistance, 
hyperlipidemia, vasculopathy, and atherosclerosis and rats that are normal and 
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homozygous (+/+) or heterozygous (+/-) do not develop any metabolic disease and are 
lean (Russell et al. 1998).  
2.3 Preparation of adipose tissue conditioned medium 
Adipose tissue was isolated from 3-6 months old Sprague-Dawley rats, heart failure 
(Sham and CAL) rats and JCR (lean and obese) rats and transferred to culture dishes 
containing Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12). 
Adipose tissue was weighed and minced into small pieces with a surgical blade mounted 
on scalpel (about 50 strokes in criss-cross section) in the same culture dish. The tissue 
was cut with a pair of scissors to ensure that all pieces were cut uniformly and as small 
as possible; any visible blood capillaries and clots were removed. Then 3-dimentional 
collagen gel (Table 4) was added and mixed to make a homogenous mixture. The 
suspension was set aside for half an hour at room temperature to solidify. After 
solidification, serum free media was added onto the gel and put in the incubator at 37oC 
5% CO2 for 24 hours. Adipose tissue conditioned medium (ACM) was then collected to 
use in the experiment. Adipose tissue conditioned medium from JCR (lean and obese) 
rats was kindly provided by Dr. Spencer Proctor (the University of Alberta). 
2.4 Cell surface area analysis of cardiomyocytes 
Cardiomyocytes were allowed to grow in serum-containing medium for 24 hours then 
were washed with PBS-ABC and again allowed to grow in serum-free medium for 24 
hours before treatment. Cells were treated with serum free medium (control) and various 
dilutions of ACM obtained from normal Sprague-Dawley, heart failure and JCR rats in 
the presence or absence of ET-1, Ovine super-active leptin antagonist (LRA), 
adiponectin receptor-1 antibody (ARA), AMPK activator AICAR, AMPK inhibitor 
dorsomorphine (Compound C) (table 5) for 24 hours. One hour time difference was kept 
before adding another chemical in the same culture dish. Cell surface area was analyzed 
using a Leica inverted microscope equipped with an infinity 1 camera at 100 x 
magnification. Cell surface area was measured using SigmaScan Software (Systat, 
Richmond, CA, USA). 
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2.5 RNA isolation and purification 
Following the treatments, total RNA from cells was extracted using TRIzol® Reagent 
(Bio-Rad Laboratories Ltd., Mississauga, ON) according to the manufacturer’s 
instructions. Briefly, following 24 hours of treatment, growth media was removed from 
cardiomyocytes dish and washed with PBS ABC. TRIzol® Reagent was added to each 
culture dish and cells were lysed and homogenized by using a cell scrapper. This 
homogenized sample was transferred to small Eppendorf tubes and kept at room 
temperature for 5 minutes to allow complete dissociation of the nucleo-protein complex. 
Chloroform was added and the tubes were shaken vigorously for 15 seconds by hand 
and incubated at room temperature. This mixture was centrifuged at 10,000 rpm for 30 
minutes at 4 oC and separated in 3 phases: lower red phenol-chloroform phase, an 
interphase, and a colourless upper aqueous phase. The aqueous phase was removed 
using a pipette and transferred to a new Eppendorf tube. Isopropanol (100%) was added 
to the aqueous phase and kept overnight at -20 oC. The following day, the sample was 
centrifuged at 10,000 rpm for 20 minutes at 4 oC. The RNA is often invisible before 
centrifugation, and forms a gel-like pellet on the side and bottom of the tube. 
Supernatant was discarded from the tube, leaving only the RNA pellet. Ethanol (75%) 
was added to the tube to wash the RNA. The tube was vortexed briefly, then centrifuged 
at 10,000 rpm for 10 minutes at 4 oC. The RNA pellet stuck to the bottom, the 
supernatant was removed and the pellet was air dried for only 10 minutes so to prevent 
loss of solubility. The RNA pellet was dissolved in Diethylpyrocarbonate (DEPC) 
treated water. The RNA was quantified using MD SpectraMax M5e Reader (Molecular 
devices, Sunnyvale, CA, USA).  
2.6 First-strand cDNA synthesis 
Four microgram RNA was used to synthesize the first strand of cDNA using Moloney 
murine leukemia virus reverse transcriptase (M-MLV RT) according to the 
manufacturer’s protocol and was used as a template in the polymerase chain (PCR) 
reactions. The cDNA synthesis was performed in nuclease-free micro-centrifuge tube. 
First 4 µg of RNA was added in the tube and DEPC treated water was added to make up 
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a 10 µl volume. Then 1x random primer and 5 mM Deoxynucleoside triphosphates 
(dNTP) mix was added to the same tube (Table 6). This mixture was heated to 65 oC for 
5 minutes and quickly chilled on ice. After brief centrifugation, the contents of the tube 
were collected and 5x FSB, 0.1 M DTT and M-MLV RT were added and mixed gently 
up and down using a pipette. The tube was incubated at 25 oC for 10 minutes followed 
by 37 oC for 50 minutes and the reaction was inactivated by heating it to 70 oC for 15 
minutes. All the reagents were from Invitrogen, Life Technologies Inc, Burlington, ON, 
Canada. 
2.7 Quantitative Real-time PCR 
The expression of the genes was performed in 10 µl reaction volumes using EvaGreen 
qPCR Mastermix (Applied Biological Materials Inc., Richmond, BC, Canada) and 
fluorescence was measured and quantified using CFX96 Touch™ Real-Time PCR 
Detection System (Bio-Rad Laboratories Ltd., Mississauga, ON, Canada). The Real-
Time PCR reaction was carried out in 96 well plates from Bio-Rad and each well 
contained 10 µl mixture of components (Table 7). The PCR consists of amplification of 
gene for 35-40 cycles with temperature changes. The PCR reaction steps consists of 
initialization step (heating the samples at 95 oC for 3 minutes), denaturation step 
(samples are heated at 95 oC for 30 seconds as this step separates DNA templates by 
disrupting the hydrogen bonds thus producing single-stranded DNA), annealing step 
(samples are cooled to 50-60 oC for 20 seconds which results in primers binding to the 
single-stranded DNA) and elongation step (samples are heated at 72 oC so that taq 
polymerase enzyme synthesizes a new complementary DNA strand). The primer 
sequences used for TPT1 (tumor protein, translationally-controlled 1), ANP, α-skeletal 
actin, leptin, adiponectin OBRb and adipoR1 are shown in table 8. TPT1 mRNA 
expression was used as a control.  
2.8 Adipokines analysis in ACM 
ACM from normal rats (except adiponectin concentration), JCR rats and heart failure 
rats was analyzed for adipokine concentrations by Eve Technologies, Calgary, AB.  The 
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analysis is based on color-coded polystyrene beads. Red and infrared dyes are used to 
create unique coloured bead sets and each unique coloured bead is bound with different 
antibody. The bead analyzer identifies the unique colour and it contains dual laser 
system. Fluorescent dye that identifies the antibody, which is within the beads, is 
activated by one laser and the other laser stimulates the streptavidin-phycoerythrin 
(fluorescent conjugate) that binds with the beads in the essay. The conjugate is detected 
by the analyzer is proportionate to the target antibody and the results are obtained using 
standard curve.  
2.9 ELISA analysis for adiponectin content in normal 
ACM   
ACM was used to determine the adiponectin content using enzyme-linked 
immunosorbent assay kit (ELISA) according to manufacturer’s instructions (EMD 
Millipore, Etobicoke, ON, Canada). Briefly, all the samples were brought to room 
temperature before starting the assay. A 96-well plate in the kit was used, washed with 
wash buffer and the plate was inverted to remove the residue of wash buffer. Assay 
running buffer was added to each well and rat adiponectin standard was added in 
ascending concentration to the proper well. Rat adiponectin quality control was added in 
appropriate wells followed by the sample. The plate was covered with plate sealer, 
placed on the shaker and incubated at moderate speed. After incubation, the plate sealer 
was removed and tapped to remove residual solutions. Wells were washed, detection 
antibody was added to each well and the plate was covered with plate sealer. After 
incubation it was washed again. Enzyme solution was added, washed, substrate solution 
was added, covered with plate sealer and incubated for 5 to 25 minutes depending on the 
development of blue colour in the wells. After colour development, the stop solution 
was added to each well and plate was gently shaken to ensure complete mixing. The 
formation of yellow colour indicated complete reaction. The plate was then read for 
absorbance at 450 nm and 590 nm and the difference between these absorbances was 
recorded.  
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2.10 Western blotting 
Cells were treated with appropriate compounds and washed with cold PBS-ABC. PBS-
ABC was discarded completely without drying the cells and lysis buffer containing 
various compounds (Table 9) and protease inhibitors were added. The cells were 
scrapped using scrapper and transferred into small tubes which were then kept on ice. 
The lysates were pipetted several times to ensure complete breakage of the cells in the 
buffer. The tubes were centrifuged at 10,000 rpm for 30 minutes. The solution had two 
forms: clear solution at the top and pellets at the bottom. Clear solution was removed 
and transferred to other small tubes leaving the pellets in the tube. This clear solution 
was transferred to the 48-well plate and then appropriate Bio-Rad protein essay solution 
was added. Following the addition of protein essay, plates were read for absorbance at 
495 nm and the amount of protein was determined using standard curve. 50 µg 
(adiponectin, AdipoR1, p-AMPK and OBRb) to 80 µg (leptin) protein was used to 
prepare samples and 6x sample buffer was added. Theses samples were heated at 100 oC 
for 10 minutes. Then sodium dodecyl sulfate (SDS) containing polyacrylamide gels 
were prepared. 7.5% (for OBRb), 10% (for adiponectin AdipoR1 and p-AMPK) and 
12% (for leptin) gels were made.  
Gels were transferred into the box and the box was filled with 1x Running Buffer (Table 
10). 8 µL protein marker (Bio-Rad) was loaded in one well and samples were loaded 
into other wells of the gel. The whole box was connected to the power source and 
constant 100 mV electric current was provided. The proteins were then separated 
according to their molecular weight on to the gels; high molecular weight proteins were 
separated at the top of the gel and low molecular weight protein remained at the bottom 
of the gel. Electric current was stopped and the gels were transferred on to the cassette 
sandwich containing sponge, filter paper, nitrocellulose membrane (20 µm and 45 µm, 
according to the protein of interest), gel, filter paper and sponge.  
This sandwich was then transferred to another box and filled with 1x Transfer Buffer 
which was then connected to a power unit. Constant 30 mA electric current was 
provided and the whole assembly was placed at 4 oC room temperature for overnight 
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transfer. The following day, membranes were removed, transferred to the box and the 
membranes were stained with Ponceau S solution to check transfer efficiency and 
protein quality. Following the staining, Ponceau S solution was discarded and 
membranes were washed with 1x Wash Buffer three times for 10 minutes each to 
remove residue from the solution completely. Membranes were blocked by 5% skim dry 
milk solution for 1 hour at room temperature on a plate shaker. The milk solution was 
discarded and the membranes were washed with wash buffer three times for 10 minutes 
each to remove the residue of the milk solution and then these membranes were probed 
with the primary antibody of leptin, OBRb, adiponectin, AdiopR1, p-AMPK, β-Actin 
and AMPK (Table 11). The boxes were kept on the shaker overnight at 4 oC. The 
following day, the membranes were kept on a shaker for one hour at room temperature. 
The membranes were then washed with wash buffer three times for 10 minutes each to 
remove the primary antibody completely from the membrane and proper secondary 
antibody was added. The boxes were kept on the shaker for one hour. After one hour the 
membrane was washed again with wash buffer thrice. The membranes were then read 
using Odyssey Clx Infrared Imaging System (Li-COR) (Lincoln, NE, United States). 
The blots were analyzed using FluorChem 8000 software. 
2.11 Molecular weight cut-off filter 
To filter the ACM we used Amicon® Ultra-15 Centrifugal Filter (3kDa and 30kDa) 
devices according to manufacturer’s instructions (EMD Millipore, Etobicoke, ON, 
Canada). Briefly, ACM was added in the tubes provided with kit and the tubes were put 
into fixed angle rotor centrifuge. The centrifuge was run at 5,000 x g for 30 minutes. At 
the end of the run, tubes were removed from centrifuge and the solution was withdrawn 
using pipette. This filtered and remained medium was used in the experiment. 
2.12 Statistical analysis 
All the experiments were analyzed using GraphPad Prism 6 and the data were 
transformed into fold change. Mean value of all the controls in each experiment was 
used to divide with each treatment value to get the fold change expression. The 
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statistical outcome was identical when raw values and fold change values were used as 
the fold change values were normally distributed. All data are represented as mean ± 
standard error mean (SEM). 
Data for cell surface area and fetal gene expressions were analyzed using 1-way analysis 
of variance (ANOVA) followed by a post hoc Tukey test. Data for the concentration 
response curve of ACM in the presence or absence of LRA and ARA were analyzed by 
2-way ANOVA followed by Bonferroni post hoc test. Data for JCR and heart failure 
rat’s characteristics and analysis of adipokines in ACM were analyzed using Student’s 
unpaired t-test. P < 0.05 was considered significant. 
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Chapter 3: Results 
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3. Results 
3.1 ACM attenuates ET-1-induced cardiomyocyte 
hypertrophy 
Cardiomyocytes were treated with ET-1 (10 nM) and in the presence or absence of 
different dilution of ACM (20x108, 10x108, 5x108, 2.5x108 and 1.25x108) for 24 hours. 
Higher dilution of ACM contains lower concentration of ACM and lower dilution of 
ACM contains higher concentration of ACM. Figure 4A shows the changes in the size 
of cardiomyocytes with the treatment of ET-1 with or without ACM. ET-1 increased 
cardiomyocytes surface area significantly (P < 0.001) compared with untreated 
cardiomyocytes and it was completely attenuated by higher concentrations of ACM 
(5x108, 2.5x108 and 1.25x108) treatment significantly (P < 0.05, 0.001 and 0.001, 
respectively) (Figure 4B and 4C). ET-1 significantly (P < 0.05) up-regulated expression 
of ANP and α-Skeletal actin which was significantly (P < 0.05) attenuated by higher 
concentration of ACM (1.25x108) treatment (Figure 1D and 1E). Lower concentration of 
ACM (20x108) did not show any significant effect on ET-1-induced cardiomyocyte 
hypertrophy (Figure 4B, 4C, 4D and 4E). In addition, cardiomyocytes treated only with 
the higher concentration of ACM (1.25x108) also did not show any difference on the cell 
surface area and fetal genes in contrast with untreated cardiomyocytes (Figure 4B, 4C, 
4D and 4E). 
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Fig. 4. ET-1–induced hypertrophy in cardiomyocytes is attenuated by ACM. Panel 
A shows the phase-contrast micrographic images of cardiomyocytes (100X 
magnification) in the absence or presence of ET-1 with the treatment of different 
dilution of ACM for 24 hours. Panels B & C show cell surface area and % maximum 
hypertrophic response on cardiomyocyte cell surface area treated in the presence of ET-
1 and with the treatment of different dilution of ACM for 24 h. Panel D and panel E 
show fetal gene (α-Skeletal actin and ANP respectively) expression on cardiomyocyte 
treated in the presence of ET-1 and with the treatment of ACM for 24 h. For cell surface 
area, the mean of 50 cells were used to provide one value. Values indicate mean ± SEM 
(n=6-10). *P<0.05 and ***P<0.001 from untreated cardiomyocytes, #P<0.05 and 
###P<0.001 from ET-1. 
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3.2 Presence of adipokines in the ACM 
Experiment was conducted using undiluted ACM (200 mg/mL). The graph represents 
concentration of Adipokines ranging from nanogram to picogram.  
27 adipokines were analyzed in the ACM and it was observed that Adiponectin was the 
most secreted adipokine from adipose tissue among all and the concentration was at 
~1.2 µg/mL (Figure 5 C). Leptin concentration was at ~3.5 ng/mL. The difference 
between these two adipokine is about 1000 fold and it is believed that the ratio is 
essential to exert adipose tissue’s effect.  
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Fig. 5. Adipokines present in the ACM. Values indicate mean ± SEM (n=12). 
40 
 
3.3 Concentration response of LRA and ARA 
To determine the role of leptin and adiponectin in cardiomyocytes, we used the leptin 
receptor antagonist (LRA) to block the OBRb and AdipoR1 antibody (ARA) to block 
the AdipoR1. 
We used four different concentrations of LRA (0.01 nM, 0.1 nM, 1 nM and 10 nM) to 
determine the optimum concentration response. We used LRA in the presence of ET-1 
and treated cardiomyocytes for 24 hours. The cell surface analysis shows that the LRA 
concentrations of 0.1 nM, 1 nM and 10 nM significantly (P < 0.05, 0.01 & 0.001, 
respectively) reduced the cell surface area compared to ET-1 alone (Figure 6A). The 
LRA concentration of 0.01 nM did not attenuate cell surface area significantly.  
To determine the optimum concentration response we used four different concentrations 
of ARA (1 ng/mL, 10 ng/mL, 100 ng/mL and 1000 ng/mL) and treated cardiomyocytes 
in the presence of ET-1. We used ACM (1.25x108) in order to attenuate ET-1 effect so 
ARA could block the anti-hypertrohic effect of ACM in a concentration-dependent 
manner. The cell surface analysis show that ARA concentrations of 1 ng/mL, 10 ng/mL 
and 100 ng/mL significantly (P < 0.001, 0.01 and 0.05, respectively) blocked the cell 
surface area compared with ET-1 alone (Figure 6B). The ARA concentration of 1000 
ng/mL did not attenuate ET-1 effect.   
We used the optimum concentration of LRA (0.1 nM) and ARA (100 ng/mL), for 
determining the concentration response curve and EC50 of ACM in the presence of LRA 
and ARA (Figure 7 and 10). 
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Fig. 6. ET-induced increase in cardiomyocyte cell surface area is attenuated by 
LRA and ACM-induced decrease in cardiomyocyte cell surface area is inhibited by 
ARA in a concentration-dependent manner. Panel A and B show % maximum 
hypertrophic response in cardiomyocyte cell surface area treated with 4 different 
concentrations of LRA and ARA (respectively) in the presence of ET-1 for 24 hours. 
Values indicate mean ± SEM (n=5-6). *P<0.05, **P<0.01 and ***P<0.001 from ET-1. 
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3.4 Leptin receptor blockade increases anti-hypertrophic 
effect of ACM 
To analyze the concentration response curve and determine EC50 of ACM in the 
presence of LRA, we treated cardiomyocytes with 0.1 nM concentration of LRA and 
with ET-1 in the presence of different dilution of ACM for 24 hours (Figure 7). The 
graph was plotted on the scale of percentage maximum hypertrophic response and 
hypertrophic assessment was performed. The cell surface area and α-Skeletal actin gene 
expression analysis show that anti-hypertrophic effect of ACM is increasing in the 
presence of LRA compared with ACM in the absence of LRA. EC50 analysis show that 
cell surface area shifts EC50 to the left from dilution of 3.125x10
8 to 8.75x108 (Figure 
7A). Similarly, the α-Skeletal actin gene expression shows that the EC50 shifts from the 
dilution 3.825x108 to 9.375x108 (Figure 7B). 
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Fig. 7. In the presence of LRA, the anti-hypertrophic effect of ACM increases in a 
concentration-dependent manner. Panel A shows the effect of LRA on cell surface 
area and EC50 shifts from dilution 3.125x10
8 to 9.375x108. Panel B shows the effect of 
LRA on α.Skeletal actin gene expression and EC50 shifts from dilution 3.825x108 to 
9.375x108. Cardiomyocytes were treated with ET-1 with ACM and with and without 
LRA for 24 hours. Values indicate mean ± SEM (n=6). ###P<0.001 from ET-1+ACM. 
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3.5 ACM down-regulates gene expression of leptin and 
OBRb 
We looked at leptin and OBRb genes expression to determine the change during ACM-
induced anti-hypertrophic effect. Cardiomyocytes treated in the presence of ET-1 for 24 
hours significantly (P < 0.05) up-regulated leptin and OBRb gene expression which was 
significantly (P < 0.05) down-regulated by higher concentration of ACM (1.25x108) 
(Figure 8). Lower concentrations of ACM did not down-regulate leptin and OBRb gene 
expression compared with ET-1. Treatment of high concentration of ACM alone did not 
show any significant effect on these gene expressions in contrast with untreated 
cardiomyocytes. 
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Fig. 8. ET-1-induced up-regulation in leptin gene and leptin receptor (OBRb) gene 
are attenuated by ACM in concentration-dependent manner. Panel A and B show 
leptin and OBRb mRNA expression, respectively, treated in the presence or absence of 
ET-1 and with the treatment of ACM for 24 h. Values indicate mean ± SEM (n=6-8). 
*P<0.05 from untreated cardiomyocytes, #P<0.05 from ET-1. 
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3.6 ACM down-regulates protein expression of leptin and 
OBRb 
To address the intracellular changes in the protein expressions during anti-hypertrophic 
effect of ACM, we carried out the protein expression of leptin (16kDa) and OBRb 
(120kDa). The treatment of ET-1 significantly (P< 0.01) up-regulated leptin and OBRb 
protein expressions in cardiomyocytes which was significantly (P < 0.05) down-
regulated by higher concentrations of ACM (2.5x108 and 1.25x108) (Figure 9). Lower 
concentrations of ACM did not show significant change in leptin and OBRb protein 
expressions compared with ET-1.  
49 
 
 
50 
 
Fig. 9. ET-1-induced up-regulation of leptin and OBRb protein expression is 
abolished by ACM in a concentration-dependent manner. Panel A and B show the 
western blot and respective quantification data for leptin (16kDa) and OBRb (120kDa) 
protein expression, respectively. Cardiomyocytes were treated in the presence or 
absence of ACM with or without ET-1 for 24 hours. Values indicate mean ± SEM (n=5-
7). **P<0.01 from control and #P<0.05 from ET-1. 
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3.7 AdipoR1 blockade decreases anti-hypertrophic effect 
of ACM 
To analyze the concentration response curve of ACM in the presence of ARA, we 
treated cardiomyocytes with 100 ng/mL ARA and with ET-1 in the presence of different 
dilution of ACM for 24 hours. We analyzed the cell surface area and α-Skeletal actin 
gene expression. We observed that anti-hypertrophic effect of ACM was decreased in 
the presence of ARA compared with ACM which is evident by cell surface area and 
α.Skactin gene expression (Figure 10). EC50 analysis could not be performed in these 
experiments. 
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Fig. 10. Blocking AdipoR1 by ARA decreases the anti-hypertrophic effect of ACM 
in cardiomyocyte in a concentration-dependent manner. Panel A shows the effect of 
ARA on cell surface area and panel B shows the effect of ARA on α-skeletal actin gene 
expression. Cardiomyocytes were treated with ET-1 with ACM and with or without 
ARA for 24 hours. Values indicate mean ± SEM (n=5-7). #P<0.05 & ###P<0.001 from 
ET-1+ACM. 
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3.8 ACM up-regulates adiponectin and AdipoR1 gene 
expression 
To explore the intracellular changes associated with the anti-hypertrophic effect of 
ACM - such as adiponectin and AdipoR1 gene expression – the expression of the 
aforementioned genes were assessed in cardiomyocytes treated with ET-1 in the 
presence or absence of varying dilutions of ACM. 24 hours treatment with ET-1 
significantly (P < 0.05) down-regulated adiponectin gene expression but had no effect 
on AdipoR1 mRNA expression (Figure 11). High concentration of ACM (1.25x108) 
significantly (P < 0.05) up-regulated the adiponectin gene expression compared with the 
ET-1 (Figure 11A). AdipoR1 mRNA expression was also significantly (P < 0.01) up-
regulated compared with ET-1 (Figure 11B). Cardiomyocytes treated with ACM alone 
significantly (P < 0.01) up-regulated AdipoR1 mRNA expression (Figure 11B). There 
also is a trend in adiponectin gene.    
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Fig. 11. ACM up-regulates both adiponectin gene and AdipoR1 gene expression in 
a concentration-dependent manner. Panel A and B show adiponectin and AdipoR1 
mRNA expression, respectively, treated in the presence or absence of ET-1 and with 
varying dilutions of ACM for 24 h. Values indicate mean ± SEM (n=5-7). *P<0.05 and 
**P<0.01 from control. #P <0.05 and ##P<0.01 from ET-1. 
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3.9 ACM up-regulates protein expression of adiponectin 
and AdipoR1 
Protein expression of adiponectin (30kDa) and AdipoR1 (42kDa) during anti-
hypertrophic effect of ACM was analyzed. 24 hours treatment of cardiomyocytes with 
ET-1 did not produce any significant change in adiponectin and AdipoR1 protein 
expression compared with untreated cardiomyocytes (Figure 12A and 12B). High 
concentrations of ACM (2.5x108 and 1.25x108) significantly up-regulated adiponectin 
(P< 0.05) and adipoR1 (P < 0.05 and 0.01 respectively) protein expressions compared 
with the ET-1 alone. Lower concentrations of ACM did not show any significant 
change.  
We observed multiple bands in the western blots for both adiponectin and AdipoR1 and 
we quantified ~30kDa band for adiponectin and ~42kDa for AdipoR1. We also 
quantified other nonspecific bands, however, there was no significance difference. 
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Fig. 12. ACM up-regulates both adiponectin and AdipoR1 protein expression in a 
concentration-dependent manner. Panels A and B show the western blots and 
respective quantification data for adiponectin (30kDa) and AdipoR1 (42kDa) protein 
expression, respectively. Cardiomyocytes were treated in the presence or absence of ET-
1 and with or without ACM for 24 hours. Values indicate mean ± SEM (n=5-7). 
#P<0.05 and ##P<0.01 from ET-1. 
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3.10 Anti-hypertrophic adipokines are present above 3kDa 
molecular weight 
To determine the molecular weight of adipokines for the anti-hypertrophic effect of 
ACM, we filtered the high concentration of ACM (1.25x108) using 3kDa filter device 
which separated ACM into two phases, high molecular weight (HMW) 3kDa (>3kDa) 
and low molecular weight (LMW) 3kDa (<3kDa). We also boiled the original 
concentration of ACM (200ng/mL) to determine that the effect of ACM which is due to 
the presence of protein. We treated cardiomyocytes for 24 hours with HMW 3kDa, 
LMW 3kDa and boiled ACM in the presence of ET-1 and analyzed cell surface area 
(Figure 13). ET-1 significantly (P < 0.01) increased the cell surface area which was 
abolished by HMW 3kDa ACM (P < 0.05). LMW 3kDa and boiled ACM did not 
attenuate ET-1-induced increase in cell surface area. Cardiomyocytes treated only with 
HMW 3kDa, LMW 3kDa and boiled alone did not show any significant change in cell 
surface area compared with untreated cardiomyocytes. 
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Fig. 13. Anti-hypertrophic adipokines are present above 3kDa. The graph shows the 
cell surface area analysis of cardiomyocytes treated with LMW ACM (<3kDa), HMW 
ACM (>3kDa) and boiled ACM and in the presence or absence of ET-1 for 24 hours. 
Values indicate mean ± SEM (n=5-8). **P<0.01 from control and #P<0.05 from ET-1. 
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3.11 Anti-hypertrophic adipokines are present below 30kDa 
molecular weight 
To determine the molecular weight range of adipokines which show anti-hypertrophic 
property during ACM treatment on ET-1-induced cardiomyocytes hypertrophy, we 
filtered high concentration ACM (1.25x108) using a 30kDa filtration device which 
separated ACM in HMW 30kDa and LMW  30kDa ACM. Cardiomyocytes were treated 
with ET-1 and in the presence or absence of HMW 30kDa and LMW 30kDa for 24 
hours and were subjected to hypertrophic assessment. ET-1 significantly increased cell 
surface area (P < 0.05) which was significantly attenuated by LMW 30kDa ACM (P < 
0.001) (Figure 14A). ET-1-induced significantly up-regulated α-Skeletal actin and ANP 
gene expression (P < 0.05 and 0.01, respectively) and it was down-regulated by LMW 
30kDa ACM significantly (P < 0.05 and 0.01, respectively) (Figure 14A and 14B). 
HMW 30kDa ACM in the presence of ET-1 did not attenuate the increase in cell surface 
area and fetal gene expressions compared with ET-1. Moreover, treatment of 
cardiomyocytes with HMW 30kDa ACM and LMW 30kDa ACM alone did not show 
any change in cell surface area or in gene expression. 
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Fig. 14. Anti-hypertrophic adipokines are present below 30kDa. Panel A shows 
cardiomyocyte cell surface area analysis treated with ET-1 and with or without the 
treatment of HMW ACM (>30kDa) and LMW ACM (<30kDa) for 24 h. Panel B and 
panel C show fetal gene (α-Skeletal actin and ANP respectively) expression on 
cardiomyocytes treated in the presence or absence of ET-1 and with the treatment of 
HMW ACM and LMW ACM for 24 h. Values indicate mean ± SEM (n=6). *P<0.05, 
**P<0.01 & ***P<0.001 from Control, #P<0.05, ##P<0.01 from ET-1 & ¥P<0.05, 
¥¥P<0.01 from ET-1 + >30kDa. 
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3.12 Effect of ACM isolated from epididymal and perirenal 
adipose tissue  
Our previous results have suggested that ACM show anti-hypertrophic effect on ET-1-
induced cardiomyocytes hypertrophy. We wanted to observe the effect of ACM isolated 
from different parts of the visceral region; epididymal and perirenal. We obtained the 
ACM from both region and carried out the hypertrophic assessment. Cardiomyocytes 
were treated with different dilutions of both ACM in the presence or absence of ET-1 
for 24 hours. Hypertrophic assessment of both types of ACM show similar trends and 
the ability to attenuate ET-1-induced hypertrophic effect in concentration-dependent 
manner (Figure 15). Lower dilution of both ACM (20x108) did not affect the increased 
cell surface area whereas all the other dilutions showed significant inhibition in ET-1-
induced increase in cell surface area (Figure 15A and 15B). Similarly, ANP and 
α.Skeletal actin gene expression was significantly (P < 0.05 and 0.01 wherever 
applicable) up-regulated in the presence of ET-1 which was significantly attenuated by 
higher concentration of both epididymal and perirenal ACM (1.25x108) (P < 0.05 and 
0.01 wherever applicable) (Figure 15C, 15D, 15E and 15F). 
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Fig. 15. ET-1–induced cardiomyocyte hypertrophy is inhibited by both ACM 
(epididymal and perirenal) in a concentration-dependent manner. Panel A and B 
show cardiomyocyte cell surface area treated in the presence or absence of different 
dilutions of both ACM and with or without ET-1 for 24 h. Panel C & D and panel E & F 
show fetal gene (α-Skeletal actin and ANP respectively) expression on cardiomyocyte 
treated in the presence of ET-1 and with the treatment of both ACM (epididymal and 
perirenal) for 24 h. Values indicate mean ± SEM (n=6-8). *P<0.05, **P<0.01 & 
***P<0.001 from untreated cardiomyocyte, #P<0.05, ##P<0.01 & ###P<0.001 from 
ET-1. 
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3.13 Effect of obesity on the ability of ACM to inhibit ET-1-
induced cardiomyocyte hypertrophy  
We obtained ACM from lean and obese JCR rat’s adipose tissue and treated 
cardiomyocytes with or without ET-1 in the presence of different dilutions of ACM 
(20x108, 1.25x108 and 1 (original concentration)) and hypertrophic assessment was 
carried out. ET-1-induced significantly increased in cell surface area (P < 0.001) was 
significantly attenuated by high concentrations of ACM from lean adipose tissue 
(1.25x108 and 1) (P < 0.001 and 0.01 respectively) (Figure 16A). Similarly α-Skeletal 
actin and ANP gene expression was significantly up-regulated by ET-1 (P < 0.05) 
which was significantly down-regulated by high concentrations of ACM from lean 
adipose tissue (1.25x108 and 1) (P < 0.05) (Figure 16A and 16B). Lower concentration 
of ACM from lean adipose tissue (20x108) did not show any significant difference 
compared with ET-1. Cardiomyocytes treated with ACM (1.25x108) from both types of 
adipose tissue in the absence of ET-1 did not show any difference in both cell surface 
area and fetal gene expression compared with untreated cardiomyocytes. Different 
dilutions of ACM from obese adipose tissue also did not show any significant difference 
in cell surface area and fetal gene expression compared with ET-1.  
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Fig. 16. ACM obtained from JCR obese rat’s adipose tissue does not attenuate ET-
1-induced cardiomyocyte hypertrophy. Panel A shows cardiomyocyte cell surface 
area treated in the presence or absence of ET-1 and with the treatment of different 
dilution of ACM obtained from JCR lean and obese rat’s adipose tissue for 24 h. Panel 
B and panel C show fetal gene (α-Skeletal actin and ANP respectively) expression on 
cardiomyocytes with or without ET-1 and with the treatment of both types of ACM for 
24 h. Values indicate mean ± SEM (n=6). *P< 0.05 & ***P<0.001 from Control and 
#P<0.05, ##P<0.01 & ###P<0.001 from ET-1. 
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3.14 JCR rats: characteristics of the heart and adipokines 
released by adipose tissue in both lean and obese rats 
The obese JCR adipocytes from epididymal region were bigger in size compared to lean 
JCR adipocytes (Figure 17A) and quantification data showed significant (P < 0.01) 
difference in the adipocyte size in obese JCR rats compared to lean JCR rats (Figure 
17B) (Figure of adipocyte was kindly provided by Dr. Spencer Proctor, the University 
of Alberta). 
The characteristics of these JCR rats showed that obese rats had significantly (P < 
0.001) higher body weight (BW) and significantly lower heart weight (HW) (P < 0.001) 
than lean JCR rats (Figure 18). Left ventricular weight (LVW) had no significant effect 
in both lean and obese JCR rats. 
Original concentration of ACM (200 mg/mL) from JCR (lean and obese) rat’s adipose 
tissue was used to determine the adipokines release. Leptin levels were significantly (P 
< 0.0065) higher, adiponectin levels were significantly (P < 0.0001) lower and  leptin 
and adiponectin ratio (L/R ratio) was significantly higher (P < 0.0065) in the ACM from 
obese JCR rat’s adipose tissue compared with ACM from lean JCR rat’s adipose tissue 
(Figure 19). Other adipokines were at similar concentration in both lean and obese JCR 
ACM (Figure 20). 
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Fig. 17. JCR obese rat’s epididymal adipocytes have significantly bigger area than 
JCR lean rat’s epididymal adipocytes. Panel A and B shows representative images 
(20X magnification) of adipocytes and relative quantification of adipocyte area of lean 
and obese JCR rat’s epididymal adipose tissue, respectively. Histological slides were 
stained with hematoxylin and eosin stain (H&E stain). Image J was used to trace seven 
adipocytes on each section. Total area was analyzed and then divided by seven to get 
average adipocyte area. Values indicate mean ± SEM (n=3). **P< 0.01 lean JCR rats. 
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Fig. 18. JCR obese rats show significant increase in body weight compared with 
JCR lean rats. Panel A shows body weight, panel B shows HW, panel C shows LV 
weight, panel D shows HW/BW and panel E shows LVW/HW. Values indicate mean ± 
SEM (n=6). *P<0.05 & ***P<0.001 from JCR lean rats. 
75 
 
 
 
Fig. 19. Leptin and adiponectin levels are significantly higher in the ACM from 
obese JCR rat’s adipose tissue. The panel A shows leptin concentration, panel B 
shows adiponectin concentration and panel C shows leptin/adiponectin ratio in the ACM 
released by lean and obese JCR rat’s adipose tissue. Values indicate mean ± SEM (n=6). 
**P<0.01 & ***P<0.001 from lean JCR rats 
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Fig. 20. There is no difference between ACM from lean and obese JCR rat’s 
adipose tissue in the levels adipokines (other than leptin and adiponectin). The 
graphs show the adipokines levels in both types of ACM from lean and obese JCR rat’s 
adipose tissue. Values indicate mean ± SEM (n=6) 
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3.15 Effect of heart failure on the ability of ACM to inhibit 
ET-1-induced cardiomyocyte hypertrophy 
ACM was obtained from both Sham and CAL rat’s adipose tissue. Cardiomyocytes 
were treated with or without ET-1 in the presence of different dilutions of ACM 
(20x108, 1.25x108 and 1 (original concentration)) from both rats and hypertrophic 
assessment was carried out. ET-1-induced significantly increased cell surface area (P < 
0.001) had significantly decreased as a result of high concentration of ACM from Sham 
rat’s adipose tissue (1.25x108 and 1) (P < 0.001) (Figure 21A). Lower concentration of 
ACM (20x108) did not show any significant difference compared with ET-1. Similarly, 
α-Skeletal actin and ANP gene expression was significantly up-regulated by ET-1 (P < 
0.05) which was attenuated by high concentrations of ACM from Sham rat’s adipose 
tissue (1.25x108 and 1) (P < 0.05) (Figure 21B and 21C). ACM from adipose tissue 
obtained from the rats subjected to CAL had no effect on ET-1 induced hypertrophy.  
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Fig. 21. ACM from CAL rat’s adipose tissue does not attenuate ET-1-induced 
cardiomyocytes hypertrophy. Panel A shows cardiomyocyte cell surface area treated 
in the presence or absence of ET-1 and with the treatment of different dilution of ACM 
obtained from the adipose tissue of CAL rats and Sham rats for 24 h. Panel B and panel 
C show fetal gene (α-Skeletal actin and ANP respectively) expression on 
cardiomyocytes treated in the presence or absence of ET-1 and with the treatment of 
ACM obtained from Sham and CAL rats adipose tissue for 24 h. Values indicate mean ± 
SEM (n=6). *P<0.05 & ***P<0.001 from untreated cardiomyocytes and #P<0.05 & 
###P<0.001 from ET-1. (CAL-coronary artery ligated) 
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3.16 Heart failure rats: characteristics of the heart and 
adipokines released by adipose tissue in both Sham 
and CAL rats  
The characteristics of heart failure rats showed that Sham and CAL rat were not 
significantly different with each other in either BW, HW or LVW (Figure 22) 
Original concentration (200 mg/mL) of ACM from Sham and CAL rat’s adipose tissue 
was used to determine the adipokines release. The analysis showed that leptin and 
adiponectin were at identical levels in both types of ACM (Sham and CAL rat’s adipose 
tissue) and L/A ratio was also not different in both types of ACM (Figure 23). Similarly, 
there was not any significant difference among all the other adipokines (Figure 24). 
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Fig. 22. There is no change in the characteristics of the BW, HW and LVW in both 
Sham and CAL rats. The graphs show the charactoristics of heart failure rats (Sham 
and CAL). Panel A, B, C, D, E show body weight, HW, LVW, HW/BW and LVW/BW, 
respectively. Values indicate mean ± SEM (n=4-5). *P<0.05 from Sham rats. 
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Fig. 23. There is no significant difference between the ACM from both Sham and 
CAL rat’s adipose tissue in the levels of leptin and adiponectin release. Panel A 
shows leptin concentration, panel B shows adiponectin concentration and panel C shows 
leptin/adiponectin ratio in both Sham and CAL rats ACM. Values indicate mean ± SEM 
(n=6-7). 
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Fig. 24. There is no significant difference in the levels of adipokines release between 
both types of ACM form Sham and CAL rat’s adipose tissue. The panels show the 
adipokines levels in the ACM from Sham and CAL rat’s adipose tissue. Values indicate 
mean ± SEM (n=6-7) 
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3.17 ACM increases AMPK activation 
To determine the signalling mechanism associated with anti-hypertrophic effect of ACM 
we focused on the signalling mechanism associated with adiponectin as it has been 
shown to attenuate cardiomyocytes hypertrophy. We focused on AMPK signalling 
mechanism. To assess the effect of ACM on p-AMPK (62kDa) we treated 
cardiomyocytes with or without ET-1 in the presence or absence of different dilution of 
ACM for 24 hours. ET-1 did not have any effect on p-AMPK protein expression (Figure 
25). High concentrations of ACM (2.5x108 and 1.25x108) increased the p-AMPK 
protein expression significantly (P < 0.05) compared with ET-1. ACM-induced 
activation of AMPK was in a concentration-dependent manner. 
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Fig. 25. ACM increases p-AMPK protein expression in a concentration-dependent 
manner. Panel above illustrates western blots for p-AMPK (62kDa) and total AMPK 
(62kDa) protein expression with relative quantification data. Cardiomyocytes were 
treated with or without ET-1 in the presence or absence of varying dilutions of ACM 
and ARA (1000 ng/mL) for 24 h.  Values indicate mean ± SEM (n=5-7). #P<0.05 from 
ET-1. 
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3.18 AdipoR1 blockade attenuates ACM-induced activation 
of AMPK  
In order to assess the role of AdipoR1 in ACM-induced activation of AMPK, 
cardiomyocytes were treated with or without ET-1 in the presence or absence of ACM 
(1.25x108) and ARA (1000 ng/mL) for 24 hours. ACM increased the p-AMPK protein 
expression in the presence or absence of ET-1 significantly (P < 0.05) compared with 
ET-1 and untreated cardiomyocytes, respectively (Figure 26). In the presence of ARA 
and ACM, p-AMPK protein expression did not show any significant change from 
untreated cardiomyocytes. Similarly, Cardiomyocytes treated with ARA alone did alter 
the basal level of p-AMPK. 
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Fig. 26. AdipoR1 blockade decreases ACM-induced increase in p-AMPK protein 
expression. Panel above shows western blot of p-AMPK and total AMPK with 
respective quantification graph. Cardiomyocytes were treated in the presence of ET-1 
and with and without ACM and AdipoR1 antibody (ARA- 1000 ng/mL) for 24 h. 
Values indicate mean ± SEM (n=6). *P<0.05 from untreated cardiomyocytes and 
#P<0.05 from ET-1. 
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3.19 Compound C (C.C) attenuates AICAR-induced anti-
hypertrophic effect in cardiomyocytes 
To determine the role of AMPK in the anti-hypertrophic effect of ACM we blocked the 
AMPK activity by using C.C which is a potent and selective AMPK inhibitor. We used 
four different concentration of C.C (0.1 µM, 1 µM, 5 µM and 10 µM) to determine the 
concentration response in ACM-induced anti-hypertrophic effect in cardiomyocytes. To 
up-regulate AMPK activation we used AICAR which is a known potent activator of 
AMPK and our lab has demonstrated that 1mM AICAR increased AMPK activity 
significantly (Javadov et al. 2009). Cardiomyocytes treated in the presence or absence of 
ET-1, AICAR and C.C for 24 hours. The cells were then subjected to hypertrophic 
assessment. ET-1 significantly increased cell surface area and α-Skeletal actin gene 
expression (P < 0.001 and 0.01, respectively) which was significantly attenuated by 
AICAR (P < 0.001 and 0.01, respectively) (Figure 27A and 27B). C.C attenuated the 
anti-hypertrophic effect of AICAR in a concentration-dependent manner. 10 µM 
concentration of C.C completely attenuated the anti-hypertrophic effect of AICAR 
which was evident by cell surface area analysis and α-Skeletal actin gene expression. 
Other concentrations of C.C did not show any significant change on α-Skeletal actin 
gene expression. Cardiomyocytes treated with 10 µM of C.C alone did not show any 
effect compared with untreated cardiomyocytes.  
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Fig. 27. Anti-hypertrophic effect of AICAR is attenuated by C.C. Panel A and B 
shows cardiomyocyte cell surface area analysis and α-Skeletal actin gene expression, 
respectively. Cardiomyocytes were treated with or without ET-1 in the presence or 
absence of AICAR (1 mM) and different concentrations of C.C (0.5-10 µM) for 24 
hours. Values indicate mean ± SEM (n=6-8). *P<0.05, **P<0.01 & ***P<0.001 from 
Control and #P<0.05, ##P<0.01 & ###P<0.001 from ET-1. 
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Chapter 4: Discussion 
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4 Discussion 
Annually, the number one cause of death worldwide is CVD (WHO 2011). 
Cardiovascular disease encompasses a multitude of pathological features. One of those 
features, which the focus of this study is dedicated to, is cardiac hypertrophy. Cardiac 
hypertrophy is a well-known risk factor for cardiovascular diseases such as heart failure, 
angina pectoris, arrhythmia and cardiac sudden death (Levy et al. 1990). Obesity is a 
disorder that accompanies many cardiovascular diseases. It is a common risk factor for, 
and thus often seen, in hypertension (Lauer et al. 1992), cardiac hypertrophy (Turkbey et 
al. 2010) and heart failure (Kenchaiah et al. 2002). Adipose tissue is distributed across 
different regions of the body, the major sites include: the visceral (epididymal, perirenal 
and mesenteric), epicardial and subcutaneous regions. Excessive accumulation of 
adipose tissue in these regions leads to obesity. This excess in adipose tissue is reported 
to be directly involved in facilitating CVD (Chess and Stanley 2008). Adipose tissue, 
after the discovery of leptin (Zhang et al. 1994), gained popularity as an endocrine organ 
which synthesises and releases adipokines. Adipokines include pro-inflammatory and 
anti-inflammatory factors (Ouchi et al. 2003, Berg and Scherer 2005, Zoccali et al. 
2005). Studies have shown that these adipokines play a critical role in modulating 
homeostasis in an autocrine, paracrine and endocrine manner. These adipokines exert 
their effects on energy metabolism, the immune system, insulin sensitivity and 
inflammation (Trayhurn and Wood 2004, Otero et al. 2005). Two particular adipokines, 
leptin and adiponectin, are known to regulate cardiac function by being functionally 
antagonistic to one another: leptin is a hypertrophic (Rajapurohitam et al. 2003, Zeidan 
et al. 2008) agent whereas adiponectin is an anti-hypertrophic agent (Shibata et al. 2004, 
Rajapurohitam et al. 2013). The interplay between these two adipokines may represent 
the link between obesity and heart failure. The presumption is that increased levels of 
adipocyte-derived leptin and decreased levels of adipocyte-derived adiponectin promote 
cardiac hypertrophy – with eventual progression to heart failure.   
Preventing cardiovascular implications is a global concern. Interaction of adipose tissue 
and the heart may allow researchers to target CVDs and explore new therapeutic 
approaches. Based on this hypothesis this thesis delves into the potential interaction 
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between adipokines and cardiomyocytes. We mimicked the pathological condition of 
the body where adipose tissue affects the heart via autocrine and paracrine mechanisms 
by using in vitro experiment techniques. To observe the interaction between adipose 
tissue and the heart we subject cardiomyocytes to ACM and assessed the degree of 
cardiomyocyte hypertrophy induced by ET-1.  
4.1 The effect of ACM on ET-1-induced cardiomyocyte 
hypertrophy 
Cardiac hypertrophy is characterized by increases in the cardiomyocyte cell surface 
area, enhanced rate of protein synthesis (Sugden and Clerk 1998) and re-expression of 
the fetal genes β- MHC, α-Sk.actin and ANP (Hefti et al. 1997). ET-1 is a 
vasoconstrictor hormone and it is not only produced by vascular endothelial cells 
(Yanagisawa et al. 1988) but also by cardiomyocytes (Nunez et al. 1990, Suzuki et al. 
1993, Yamazaki et al. 1996), cardiac fibroblasts (Fujisaki et al. 1995) and macrophages 
(Fukuchi and Giaid 1998). The levels of ET-1 are elevated during obesity and cardiac 
hypertrophy (Barton et al. 2003). ET-1 acts via the ETA and ETB receptors. ETA receptor 
is widely expressed by myocardium (Molenaar et al. 1993) and by cardiomyocytes (Ito 
et al. 1993). Production and expression of the ET-1 receptor by cardiac cells suggests 
the autocrine and paracrine role of ET-1 on the regulation of cardiac functions. Because 
of this positive association between plasma levels of ET-1 during obesity and cardiac 
hypertrophy, ET-1 was used in these cardiomyocyte in vitro experiments to induce 
cardiac hypertrophy and to study the modulation of this cardiac hypertrophy by adipose 
tissue. Studies, including those from our laboratory, have shown that a 10 nM 
concentration of ET-1 significantly induces hypertrophy in neonatal rat cardiomyocytes 
and it was marked by a significant increase in cardiomyocyte cell surface area and fetal 
gene (ANP and α.Skeletal actin) expression (Ito et al. 1991, Rajapurohitam et al. 2006, 
Kilic et al. 2010, Zeidan et al. 2014). Our results show that treatment of cardiomyocytes 
with a lower dilution of ACM (1.25 x 108) completely attenuates cell surface area and 
increases fetal gene expression significantly. This suggests an anti-hypertrophic effect of 
ACM on ET-1-induced hypertrophy, an effect which is attributed to the presence of anti-
hypertrophic adipokines. However, a higher dilution of ACM (20 x 108) did not show 
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any effect which suggests the absence of anti-hypertrophic adipokines in this higher 
dilution ACM. 
4.1.1 Role of leptin and OB-Rb in the anti-hypertrophic 
effect of ACM on cardiomyocytes 
It is well documented that leptin is produced by adipose tissue (Scherer et al. 1995). 
Plasma levels of leptin are proportionate to adiposity thus high leptin levels are observed 
during obesity and the increased levels are also associated with increased congestive 
heart failure risk (Lieb et al. 2009). Leptin levels have been linked with increased risk of 
numerous CVDs suggesting the role of leptin levels as a marker for diagnosis of CVDs 
(Schulze and Kratzsch 2005). Leptin is also produced by the heart and cardiomyocytes. 
Furthermore, leptin receptors are expressed by the heart and cardiomyocytes (Purdham 
et al. 2004, Rajapurohitam et al. 2006) suggesting an effect of leptin on the heart 
through autocrine/paracrine mechanisms and through the endocrine system. Our study 
show that by blocking the OB-Rb receptor using LRA, the anti-hypertrophic effect of 
ACM becomes more pronounce and effect of ACM is concentration-dependent. In 
addition, the result from both cell surface area and fetal gene expression shows that the 
concentration response curve shifts to the left side in the presence of LRA suggesting 
that the ACM’s anti-hypertrophic property is now more potent and cardiomyocytes are 
more sensitive to the effect of ACM. Analysis of EC50 suggests that the anti-
hypertrophic effect can be achieved with a high dilution of ACM. This may suggest 
critical involvement of the leptin receptor in the anti-hypertrophic response of ACM. 
This result is in agreement with studies from our laboratory, displaying in vitro and in 
vivo data, which demonstrates the cardio-protective effect of blocking the OB-Rb 
receptor in the presence of leptin (Rajapurohitam et al. 2006, Zeidan et al. 2006, 
Purdham et al. 2008). ACM down-regulates leptin and OBRb gene and protein 
expression whereas ET-1 up-regulates leptin and OBRb gene and protein expression in 
cardiomyocytes.  
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4.1.2 Role of adiponectin and AdipoR1 in the anti-
hypertrophic effect of ACM on cardiomyocytes 
Adiponectin is a hormone produced by adipose tissue (Scherer et al. 1995) and it is the 
most abundant circulating plasma protein in healthy individuals (Arita et al. 1999). It 
possesses anti-inflammatory, (Ouchi et al. 2003) anti-tumor (Brakenhielm et al. 2004), 
anti-angiogenesis (Brakenhielm et al. 2004) and insulin sensitizing functions (Hotta et 
al. 2000). Reduced  adiponectin levels are observed during obesity (Arita et al. 1999), 
coronary artery disease (Nakamura et al. 2004) and in heart failure patients (Takano et 
al. 2009). Plasma adiponectin levels are significantly up-regulated during weight loss in 
type 2 diabetes mellitus and in healthy subjects (Hotta et al. 2000). This suggests an 
inverse relationship between adiposity and adiponectin. Adiponectin has been known to 
regulate homeostasis because of its wide variety of functions in other organs including 
improving insulin sensitivity in the liver (Nawrocki et al. 2006) and fatty acid oxidation 
in skeletal muscle (Fruebis et al. 2001).  
Adiponectin plays a cardio-protective role which is evident from a number of studies. A 
study on adiponectin deficient mice demonstrated that exogenous adiponectin 
administration protected the heart from myocardial apoptosis, increased infract size and 
ischemic perfusion injury (Shibata et al. 2005, Tao et al. 2007). Another study 
demonstrated that adiponectin knockout mice showed significant cardiac remodelling 
induced by pressure overload  on the heart compared with wild type mice (Liao et al. 
2005). These studies suggest an anti-hypertrophic role for adiponectin. Neonatal 
cardiomyocytes express more AdipoR1 receptor than AdipoR2 receptor (Palanivel et al. 
2007). The protective effect of adiponectin against ischemic reperfusion injury is 
mediated through the AdipoR1 receptor (Wang et al. 2010). Adiponectin has also been 
shown to protect rat embryonic cardiac myoblasts (H9c2) from hypoxia/reoxygenation 
injury via AdipoR1-mediated signaling (Park et al. 2011). A recent study shows that 
adiponectin protects atrial cardiomyocytes from Ang II-induced hypertrophy which was 
found to be mediated by the AdipoR1 receptor (Cao et al. 2014). Our results show that 
in the presence of ARA the concentration response curve of the ACM shifted to the right 
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side which indicates a decrease in potency of the ACM in cardiomyocytes resulting in a 
desensitization of the cardiomyocytes to the anti-hypertrophic effect of the ACM. Which 
also displays that for the same anti-hypertrophic effect of ACM, a greater amount of 
ACM is needed in the presence of ARA. This result suggests that the anti-hypertrophic 
effect of ACM is dependent on signalling through the AdipoR1 receptor. ACM up-
regulates adiponectin and AdipoR1 gene and protein expression during ET-1-induced 
hypertrophy and this up-regulation in gene and protein expression contributes towards 
the anti-hypertrophic effect of the ACM. 
4.1.3 Levels of adipokines in ACM 
Analysis of the ACM showed that adiponectin was secreted abundantly and 
concentration of leptin was ~3.5 ng/mL and adiponectin was ~1.2 µg/mL. This analysis 
of levels of adipokines in the ACM would help us to better appreciate the ACM 
obtained from the adipose tissue undergoing a pathological condition.  
4.1.4 Molecular weight of anti-hypertrophic adipokines 
Narrowing down the molecular weight range for the anti-hypertrophic effect of ACM 
lead us to filter the ACM and the results showed that the anti-hypertrophic adipokines 
were present between the molecular weight range of 3-30kDa. This suggests the 
possibility of involvement of leptin and adiponectin for the anti-hypertrophic effect. 
Results from the boiled medium showed no effect on cardiomyocytes with or without 
ET-1 which confirmed the involvement of proteins in the anti-hypertrophic effect of the 
ACM. 
4.1.5 Effect of adipose tissue from different region 
Studies have reported that adipose tissue from different regions of the body have 
different effects. There is a positive relation between abdominal obesity and increased 
likelihood of hypertension (Cassano et al. 1990), obstructive sleep apnea (Schafer et al. 
2002) and type 2 diabetes mellitus (Chan et al. 1994). One study observed that increased 
adipose tissue around the legs was protective against impaired glucose levels (Snijder et 
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al. 2004). These studies suggest that different regions of adipose tissue may have 
different effects. Therefore we hypothesized that adipose tissue from epididymal and 
perirenal regions will exert different effects on neonatal rat cardiomyocyte hypertrophy. 
Results from our study showed that the ACM, regardless of the particular body region 
the adipose tissue was obtained from, exerted identical anti-hypertrophic effects. This 
result was analyzed by the hypertrophic assessment of both types of ACM during ET-1-
induced cardiomyocytes hypertrophy. This suggests that the adipose tissue obtained 
from different regions of the body contains the same anti-hypertrophic adipokines and 
that the ACM remains cardiomyocyte-protective irrespective of the particular body 
region the adipose tissue was resected from. 
4.1.6 Effect of ACM obtained from adipose tissue during 
pathological condition 
Our aim was to better understand the ACM response and adipokine profile obtained 
from the adipose tissue of an animal in a pathological state. We hypothesize that the 
adipose tissue taken from an animal undergoing a pathological condition will modulate 
the hypertrophic response of ET-1. In addition we hypothesize that the levels of 
adipokines will also change. To explore this hypothesis we used an obese animal model 
and heart failure animal model. 
4.1.7 Role of ACM from obese rats 
It is well known that obesity exacerbates several CVDs including cardiac hypertrophy 
(Turkbey et al. 2010) and heart failure (Kenchaiah et al. 2002). To study the link 
between obesity and cardiac hypertrophy and the involvement of adipose tissue we used 
JCR strain rats. JCR (Jcr:LA-cp) is a unique strain that was originated from LA/N strain 
and fifth backcross with LA/N-cp and breeding stock from NIH, Maryland was sent to 
JC russell’s lab at the University of Alberta. These rats carries the mutant autosomal 
recessive cp gene, homozygous (cp/cp) rats develop obesity, insulin resistance, 
hyperlipidemia, vasculopathy, and atherosclerosis and the rats that are homozygous 
(+/+) or heterozygous (+/-) are lean and do not develop any metabolic disease (Russell 
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et al. 1998). These rats provide a suitable model to study obesity, insulin resistance and 
CVDs which is similar to humans (Russell and Koeslag 1990). 
Our results showed that the ACM from JCR obese animals did not protect 
cardiomyocytes against the hypertrophic response induced by ET-1. In contrast, the 
ACM from JCR lean animals displayed an anti-hypertrophic effect. We believed that 
this effect is due to the alteration in the release of adipokines in the ACM (more leptin 
and less adiponectin). Analysis of released adipokines in the JCR obese ACM shows 
that leptin levels are significantly up-regulated and levels of adiponectin are 
significantly down-regulated compared with JCR lean ACM. This analysis supports the 
studies that show that obese adipose tissue releases less adiponectin (Arita et al. 1999) 
and more leptin (Maffei et al. 1995, Considine et al. 1996). This phenomenon can be 
explained by the adipose tissue remodelling that occurs during obesity (Jernas et al. 
2006, Skurk et al. 2007). This remodelling involves increases in adipocyte size (which is 
evident by images of the epididymal adipose tissue from JCR obese rats), and an 
increase in the release pro-inflammatory adipokines such as leptin, TNF-alpha which is 
accompanied by a decrease in anti-inflammatory adipokines such as adiponectin (Jernas 
et al. 2006, Skurk et al. 2007). Increased numbers of macrophages in adipose tissue are 
also observed in obesity which releases significant amounts of TNF-alpha (Weisberg et 
al. 2003). TNF-alpha has inhibitory effects on the release of adiponectin (Hector et al. 
2007). With more leptin and less adiponectin released by the obese ACM we expect to 
observe a pro-hypertrophic effect of obese ACM on cardiomyocytes. Interestingly we 
did not see any effect of obese ACM treated without any hypertrophic agonist. We 
believed that the reason behind inability of ACM to modulate the hypertrophic response 
is that, though the levels of leptin are up-regulated, they are not sufficient enough to 
induce hypertrophic response on its own. This elevation in the levels of leptin may 
contribute towards the hypertrophic effect of ET-1 in cardiomyocytes. The result from 
this study suggests that the protective effect of ACM on cardiomyocytes is blunted 
during obesity and the modulation of hypertrophic response by adipocytes is dependent 
on leptin/adiponectin ratio that is significantly high during obese condition. 
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4.1.8 Role of ACM from heart failure rats 
Studies have shown that adipokines are a potential link between obesity and heart failure 
(Schulze et al. 2003, Ouchi et al. 2006, Frankel et al. 2009, Ebert and Fasshauer 2011). 
Leptin levels are elevated whereas adiponectin levels are decreased during heart failure 
(Chan et al. 2003, Takano et al. 2009). Results from cardiomyocytes treated with ACM 
derived from the adipose tissue of both sham and CAL rats demonstrated that ACM 
from adipose tissue obtained from CAL rats did not attenuate ET-1-induced 
cardiomyocyte hypertrophy and, interestingly, this effect of both ACM could be due to 
the alteration in the release of adipokines levels. A recent study from our laboratory 
shows that CAL induced significant increases in plasma levels of leptin but there was no 
change in adiponectin levels compared with sham (Gan et al. 2014) which suggests that 
the heart failure condition increases leptin levels which may be due to adipose tissue 
remodelling. We performed the analysis to identify the levels of adipokines and 
surprisingly, we did not observe any change in the adipokine profile and both types of 
ACM showed identical levels of leptin and adiponectin and also other adipokines in 
ACM obtained from adipose tissue between Sham and CAL heart failure rats. However, 
the leptin levels in ACM were almost ten-fold higher, and the adiponectin levels were 
about 5-fold higher in both Sham and CAL heart failure rats compared with normal, 
healthy rats - suggesting the remodelling of adipose tissue in heart failure causes more 
release of leptin and adiponectin. These results raise the possibility for the involvement 
of different adipokines other than leptin and adiponectin that are playing a protective 
role in ACM obtained from adipose tissue of Sham rats and this protective effect is lost 
in ACM obtained from adipose tissue of CAL rats. A recent study by Yi at al. shows 
that a newly discovered adipokine “C1q TNF related protein-3 (CTRP3)” protects heart 
failure mice from ventricular cardiac remodelling (Yi et al. 2012). The heart failure 
condition attenuated CTRP3 gene expressions in adipose tissue resulting in decreased 
CTRP3 levels in the plasma and injecting exogenous recombinant CTRP3 with an 
intraperitoneal pump restored the plasma level of CTRP3 leading to improved left 
ventricular ejection fraction (LVEF) and survival rate. It is reported that CTRP3 
regulates adiponectin release from adipose tissue (Wolfing et al. 2008). This study 
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suggests that the heart failure condition remodels adipose tissue which suppresses the 
release of protective adipokines. This further suggests the protective effect of ACM 
from adipose tissue of sham rats is abrogated in ACM from adipose tissue of CAL rats 
and this might be due to a decrease in CTRP3. All in all, further analysis is required to 
confirm the involvement of other adipokines. 
4.2 Role of AMPK during ACM-induced anti-hypertrophic 
effect 
As we observed the anti-hypertrophic effect of ACM during ET-1-induced 
cardiomyocyte hypertrophy, we were determined to understand the signalling 
mechanism regulating the protective effect of ACM. Our primary focus was 
adiponectin-mediated signalling, as a number of studies have shown the cardio-
protection effect of adiponectin via an AMPK signalling mechanism. Adiponectin 
activates AMPK and protected the heart from ischemic perfusion injury (Shibata et al. 
2005).  Adiponectin knockout mice were unable to prevent cardiac remodelling induced 
by pressure overload conditions and they showed low expression of p-AMPK protein 
expression compared with wild type mice (Shimano et al. 2010). It has been reported 
that AMPK activates PPAR alpha to inhibit cardiac hypertrophy by down-regulating 
ERK1/2 protein expression (Meng et al. 2011). In addition, it inhibits Ang II-induced 
nuclear factor kappaB (NF-kB) activation (Wang et al. 2010) and inhibits protein 
synthesis resulting in inhibition of cardiac hypertrophy (Li et al. 2007). A recent study 
shows that the anti-hypertrophic effect of adiponectin against Ang II is mediated by 
AdipoR1 and AMPK (Cao et al. 2014). Our results show that the ACM increases p-
AMPK levels in cardiomyocytes which suggests the anti-hypertrophic effect of ACM 
involves an AMPK dependent signalling mechanism.  
As the protective effect of ACM is through activation of AdipoR1, blocking AdipoR1 
may suggest the causative or correlative role of AMPK. To further investigate the 
involvement of AdipoR1 we hypothesized that blocking AdipoR1 would also block the 
increase in p-AMPK protein expression. The protein expression of p-AMPK showed 
that ARA attenuated the ACM-induced up-regulation p-AMPK. This effect may be 
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responsible for the abolishment of the anti-hypertrophic effect caused by ARA. ET-1 
and ARA treatment alone failed to down-regulate the basal level of p-AMPK level. It is 
possible that a basal level of p-AMPK is maintained in the cardiomyocyte for normal 
function.  
To further investigate the causative or correlative role of AMPK we used C.C to block 
the AMPK activation completely. In contrast, we used AICAR to increase AMPK 
activity. AICAR is a 5-Aminoimidazole-4-carboxamide-1-β-d-ribofuranoside which is 
phosphorylated by adenosine kinase and converted into ZMP (AICA-riboside 
monophosphate) in the cytosol, which is an AMP analogue that acts as AMP and 
activates AMPK (Corton et al. 1995). Hypertrophic assessment shows that the AICAR 
treatment blocked the ET-1-induced hypertrophy in cardiomyocytes. 10 µM 
concentration of C.C completely blocked the AICAR effect. This result suggests that the 
AICAR treatment increased AMPK activation resulting in an anti-hypertrophic effect. 
This anti-hypertrophic effect was then blocked by C.C. The current study demonstrates 
that AMPK plays a causative role when AdipoR1 is blocked during ACM-induced anti-
hypertrophy. This study proceeds forward to establish a causative role for AMPK by use 
of AICAR and C.C. Future studies include assessing protein expression of p-AMPK in 
cardiomyocytes treated with ACM in the presence or absence of C.C. 
4.3 Significance and clinical perspective of the study 
As CVDs are accountable for more deaths than any other diseases worldwide, 
researchers and pharmaceutical companies are searching for new therapeutic approaches 
for CVDs to reduce the mortality rate. One leading cause of CVDs is obesity and the 
consequent secretion of adipose tissue-derived cytokines (adipokines). These adipokines 
have been the focus of research in this field because of their modulatory effect on 
homeostasis. To date there are some adipokines including leptin and adiponectin that are 
known to regulate cardiac function and their plasma levels can be considered as a strong 
predictor for CVDs. In order to better understand the relationship between CVDs and 
adipokines, they are currently being studied both in vitro and in vivo. Our study 
provides direct interaction between adipokines and cardiomyocytes and our results could 
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explain the cardio-protective role of adipokines. Adiponectin has been the centre of 
research for the therapeutic approach to treating CVDs because of adiponectin’s cardio-
protective effects through its receptors and AMPK signalling (Gu and Li 2012, 
Nanayakkara et al. 2012). Our results also suggest that the protective effect of ACM was 
due to an adiponectin-dependent effect mediated by AdipoR1 and activation of AMPK. 
The results of this thesis have been demonstrated in an in vitro system and further in 
vivo evidence is necessary to gain further confidence. The findings of the study may 
explain the role and involvement of adipokines in CVDs during physiological and 
pathophysiological conditions and targeting adiponectin, AdipoR1 or AMPK will be 
helpful for finding new therapeutic approaches for the treatment of CVDs. 
4.4 Conclusion 
The major conclusion that can be drawn from the results obtained in this study is that the 
ACM from the adipose tissue obtained from normal rats contains anti-hypertrophic 
properties against ET-1. This anti-hypertrophic effect of ACM is due to activation of 
AdipoR1 and the net anti-hypertrophic effect is dependent on the interaction of leptin 
and adiponectin in cardiomyocytes. 
The pathological situation such as obesity leads to adipose tissue remodelling resulting 
in increases in pro-inflammatory adipokine release and decreases in anti-inflammatory 
adipokine release from the tissue. Thus the anti-hypertrophic effect of ACM from 
adipose tissue obtained from JCR obese rats is abrogated due to significant up-
regulation in leptin levels and down-regulation in adiponectin levels compared with 
ACM from adipose tissue obtained from JCR lean rats.  
The signalling mechanism for the anti-hypertrophic effect of ACM is dependent upon 
up-regulation of p-AMPK though AdipoR1 signalling.  
The findings from this study may explain the beneficial effect of staying within the 
normal and healthy weight range and the adverse effect of being overweight and obese. 
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Appendices 
Appendix 1: Tables 
Table 1: Composition of culture medium reagents for neonatal cardiomyocytes 
Chemical Name Concentration Manufacturer 
DMEM/F12 1 pkg Gibco (Life Technologies 
Burlington, ON, Canada) 
NaHCO3 2.4 mg/mL Sigma-Aldrich (Oakville, 
ON, Canada) 
Fetal Bovine Serum 
(FBS) 
10% Gibco (Life Technologies 
Burlington, ON, Canada) 
HEPES 30 mM Gibco (Life Technologies 
Burlington, ON, Canada) 
Bromodeoxyuridine 0.1 mM Sigma-Aldrich (Oakville, 
ON, Canada) 
Linoleic Acid 5 µg/mL Sigma-Aldrich (Oakville, 
ON, Canada) 
Pyruvic Acid 3 mM Sigma-Aldrich (Oakville, 
ON, Canada) 
Bovine Serum Albumin 
(BSA) 
2 mg/mL Gibco (Life Technologies 
Burlington, ON, Canada) 
Penicillin/Streptomycin 1% Gibco (Life Technologies 
Burlington, ON, Canada) 
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Insulin 10 µg/mL Sigma-Aldrich (Oakville, 
ON, Canada) 
Holo-Transferrin 10 µg/mL Sigma-Aldrich (Oakville, 
ON, Canada) 
Sodium Selenite 10 ng/mL Sigma-Aldrich (Oakville, 
ON, Canada) 
L-Ascorbic Acid 100 µM Gibco (Life Technologies 
Burlington, ON, Canada) 
MEM Non-essential 
Amino Acids 
1% Sigma-Aldrich (Oakville, 
ON, Canada) 
MEM Vitamins 100X 0.1 % Sigma-Aldrich (Oakville, 
ON, Canada) 
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Table 2: Composition of PBS-ABC solution for neonatal cardiomyocytes.  
All chemicals are from Sigma-Aldrich (Oakville, ON, Canada). 
Reagent  Chemical Concentration 
PBS ABC PBS A 80% 
 PBS B 10% 
 PBS C 10% 
   
PBS A NaCl 10 g/L 
KCl 0.250 g/L 
Na2HPO4.7H2O 2.71 g/L 
KH2PO4 0.250 g/L 
PBS B CaCl2.2H2O 1.32 g/L 
PBS C MgCl2.6H2O 2.13 g/L 
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Table 3: Serum-free medium reagents for neonatal cardiomyocytes 
Chemical Name Concentration Manufacturer 
DMEM/F12 1 pkg Gibco (Life Technologies 
Burlington, ON, Canada) 
NaHCO3 2.4 mg/mL Sigma-Aldrich (Oakville, 
ON, Canada) 
Bromodeoxyuridine 0.075 mM Sigma-Aldrich (Oakville, 
ON, Canada) 
Bovine Serum Albumin 
(BSA) 
1% Gibco (Life Technologies 
Burlington, ON, Canada) 
Penicillin/Streptomycin 1% Gibco (Life Technologies 
Burlington, ON, Canada) 
Insulin 10 µg/mL Sigma-Aldrich (Oakville, 
ON, Canada) 
Holo-Transferrin 5 µg/mL Sigma-Aldrich (Oakville, 
ON, Canada) 
Sodium Selenite 10 ng/mL Sigma-Aldrich (Oakville, 
ON, Canada) 
Fetuin 250 µg/mL Sigma-Aldrich (Oakville, 
ON, Canada) 
CaCl2 80 µg/mL Sigma-Aldrich (Oakville, 
ON, Canada) 
L-Ascorbic Acid 100 µM Gibco (Life Technologies 
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Burlington, ON, Canada) 
MEM Non-essential 
Amino Acids 
1% Sigma-Aldrich (Oakville, 
ON, Canada) 
MEM Vitamins 100X 0.1% Sigma-Aldrich (Oakville, 
ON, Canada) 
BSA-Palmitate 0.2% Sigma-Aldrich (Oakville, 
ON, Canada) 
 
Table 4: Reagent composition of 3-dimentional collagen gel 
Reagent  Concentration 
Collagen, type I from rat 
tail 
60% 
10 x DMEM F-12 medium 10% 
*Reconstructive Buffer 10% 
Sterile Water 20% 
This mixture is kept on ice as it solidifies at room 
temperature 
*Reconstructive Buffer  
NaHCO2 2.2% 
HEPES 4.7% 
NaOH 0.05 M 
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Table 5: The table summarizes the chemical concentration and manufacturer. 
Chemical 
name 
Concentration manufacturer 
ET-1 10 nM Sigma-Aldrich (Oakville, ON, 
Canada) 
LRA  0.01 nM – 10 nM Protein Laboratories Rehovot 
(Rehovot, Israel)  
ARA   1 ng/mL – 1000 
ng/mL 
Santa Cruz Biotechnology 
(Santa Cruz, CA, USA) 
AICAR 1 mM Cell Signaling Technology 
(Danvers, MA, USA) 
C.C 0.5 µM – 10 µM Sigma-Aldrich (Oakville, ON, 
Canada) 
Table 6: Mixture composition for reverse transcription 
Component Volume/reaction 
(μL) 
1x Random Primer 1 
5mM dNTP mix 2 
5x First Stand Buffer (FSB) 4 
0.1M DTT 2 
MLV-RT 1 
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Table 7: Real-Time PCR reaction mixture 
Component Volume/reaction 
(μL) 
EvaGreen qPCR Mastermix 5 
Forward Primer 0.5 
Reverse Primer 0.5 
cDNA 2 
Double Distilled Water 2 
 
Table 8: Primer sequences and real-time RT-PCR conditions. 
Primers PCR parameters 
Phase Temp. 
oC  
TPT1 
Forward:5’-GGAGGGCAAGATGGTCAGTA-
3’ 
Reverse:5’-AGGCCTCTTTTGTGAAGCTG-3’ 
Denaturation 
Annealing 
Extension 
95 
58 
72 
ANP 
Forward:5’-CTGCTAGACCACCTGGAGGA-3’ 
Reverse:5’-AAGCTGTTGCAGCCTAGTCC-3’ 
Denaturation 
Annealing 
Extension 
95 
60 
72 
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α-Skeletal actin 
Forward:5′-CACGGCATTATCACCAACTG-3′ 
Reverse:5′-CCGGAGGCATAGAGAGACAG-3′ 
Denaturation 
Annealing 
Extension 
95 
60 
72 
Leptin 
Forward:5’-TGATATCGCCAAACAGCAAA-3’ 
Reverse:5’-AGTGTCCGCTCTCTTTTGGA-3’ 
Denaturation 
Annealing 
Extension 
95 
58 
72 
Adiponectin 
Forward:5’-AATCCTGCCCAGTCATGAAG-3’ 
Reverse:5’-CCACAATGATGGCAGAGATG-3’ 
Denaturation 
Annealing 
Extension 
95 
60 
72 
OBRb 
Forward:5′-TGACCACTCCAGATTCCACA-3′ 
Reverse:5′-CCACTGTTTTCACGTTGCTG-3′ 
Denaturation 
Annealing 
Extension 
95 
60 
72 
AdipoR1 
Forward:5’-TGGTCTTCGGGATGTTCTTC-3’ 
Reverse:5’-CCACAATGATGGCAGAGATG-3’ 
Denaturation 
Annealing 
Extension 
95 
60 
72 
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Table 9: Composition of lysis buffer 
Chemical  Concentration 
Tris-HCl 50 mM 
NaCl 150 mM 
Triton 1% 
Glycerol 10% 
EDTA 2 mM 
EGTA 2 mM 
NaF 50 mM 
Na3Vo4 200 µM 
Na4P2O7 10 mM 
β-Glycerophosphate 40 mM 
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Table 10: Composition of buffers used in western blotting. The pH was adjusted to 7.5. 
Chemical Running 
Buffer 
 Transfer 
Buffer 
 Wash 
Buffer 
Tris base 0.3%  0.4%  0.3% 
Glycine 1.44%  1.8%  --- 
SDS 0.1%  ---  --- 
NaCl ---  ---  0.9% 
Tween20 ---  ---  0.1% 
Methanol ---  25%  --- 
 
 
 
 
 
 
 
 
 
 
 
 
136 
 
Table 11: Details of antibodies, dilution ranges, types and manufacturers. 
Antibody Dilution Type Manufacturer 
leptin 1:500 Rabbit 
polyclonal 
Santa Cruz Biotechnology 
(Santa Cruz, CA, USA) 
OBRb 1:1000 Mouse 
monoclonal 
Alpha Diagnostics 
International, (San Antonio, 
TX, USA) 
Adiponectin 1:500 Goat 
polyclonal 
Santa Cruz Biotechnology 
(Santa Cruz, CA, USA) 
AdipoR1 1:500 Rabbit 
polyclonal 
Santa Cruz Biotechnology 
(Santa Cruz, CA, USA) 
α-AMPK 1:1000 Rabbit 
polyclonal 
Cell Signaling Technology 
(Danvers, MA, USA) 
AMPK 1:1000 Rabbit 
polyclonal 
Cell Signaling Technology 
(Danvers, MA, USA) 
β-Actin 1:1000 Rabbit 
polyclonal 
Santa Cruz Biotechnology 
(Santa Cruz, CA, USA) 
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Appendix 2: Animal use protocol approval from the Animal Use Subcommittee of the 
University Council on Animal Care 
 
AUP Number: 2013-031 
PI Name: Karmazyn, Morris 
AUP Title: Heart failure 
 
Official Notification of AUS Approval: A MODIFICATION to Animal Use Protocol 
2013-031 has been approved. 
 
The holder of this Animal Use Protocol is responsible to ensure that all associated safety 
components (biosafety, radiation safety, general laboratory safety) comply with 
institutional safety standards and have received all necessary approvals. Please consult 
directly with your institutional safety officers. 
 
Submitted by: Copeman, Laura 
on behalf of the Animal Use Subcommittee 
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